

# UC Irvine

## UC Irvine Previously Published Works

### Title

KCNE1 and KCNE3: The yin and yang of voltage-gated K(+) channel regulation.

### Permalink

<https://escholarship.org/uc/item/6bk2135x>

### Journal

Gene, 576(1 Pt 1)

### Author

Abbott, Geoffrey

### Publication Date

2016-01-15

### DOI

10.1016/j.gene.2015.09.059

Peer reviewed



# HHS Public Access

Author manuscript

Gene. Author manuscript; available in PMC 2017 January 15.

Published in final edited form as:

Gene. 2016 January 15; 576(1 Pt 1): 1–13. doi:10.1016/j.gene.2015.09.059.

## KCNE1 and KCNE3: the yin and yang of voltage-gated K<sup>+</sup> channel regulation

**Geoffrey W. Abbott**

Bioelectricity Laboratory, Dept. of Pharmacology and Dept. of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA

### Abstract


The human KCNE gene family comprises five genes encoding single transmembrane-spanning ion channel regulatory subunits. The primary function of KCNE genes appears to be regulation of voltage-gated potassium (Kv) channels, and the best-understood KCNE complexes are with the KCNQ1 Kv  $\alpha$  subunit. Here, we review the often opposite effects of KCNE1 and KCNE3 on Kv channel biology, with an emphasis on regulation of KCNQ1. Slow-activating  $I_{Ks}$  channel complexes formed by KCNQ1 and KCNE1 are essential for human ventricular myocyte repolarization, while constitutively active KCNQ1-KCNE3 channels are important in the intestine. Inherited sequence variants in human KCNE1 and KCNE3 cause cardiac arrhythmias but by different mechanisms, and each is important for hearing in unique ways. Because of their contrasting effects on KCNQ1 function, KCNE1 and KCNE3 have proved an invaluable tool in the mechanistic understanding of how channel gating can be manipulated, and each may also provide a window into novel insights and new therapeutic opportunities in K<sup>+</sup> channel pharmacology. Finally, findings from studies of *Kcne1*<sup>-/-</sup> and *Kcne3*<sup>-/-</sup> mouse lines serve to illustrate the complexity of KCNE biology and KCNE-linked disease states.

### Graphical abstract

---

Correspondence: Dr. Geoffrey W. Abbott, 360 Medical Surge II, Dept. of Pharmacology, School of Medicine, University of California, Irvine, CA 92697, USA. [abbottg@uci.edu](mailto:abbottg@uci.edu); Tel: +1-949-824-3269; Fax: +1-949-824-4855.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Keywords

auditory; cardiac arrhythmia; intestine; inherited deafness; Long QT syndrome; potassium channel; voltage-gated

## Introduction

Bioelectricity - the electrical activity generated by living organisms - is observable across all six kingdoms of life, and essential in higher animals for processes including fertilization, neuronal firing, and muscular contraction. Electrical signals are conducted primarily by ion channels, which have evolved the capability to selectively and rapidly conduct charged, aqueous ions across the hydrophobic barrier established by the plasma membrane.

Within the ion channels, the S4 superfamily contains those that respond to changes in membrane potential via a voltage sensor that includes the S4 domain. The S4 is so named because it is the fourth transmembrane (TM) segment in the 6-TM module that constitutes the pore-forming ( $\alpha$ ) subunit of eukaryotic voltage-gated potassium (Kv) channels and some prokaryotic voltage-gated sodium (Nav) and calcium (Cav) channels<sup>1</sup>. While each of these voltage-gated channel classes achieve their respective ion selectivity by distinct mechanisms, the atomic structure and signature sequence for K<sup>+</sup> selectivity is highly conserved between primitive tetrameric bacterial K<sup>+</sup> channels lacking a voltage sensor<sup>2</sup>, tetrameric mammalian Kv channels carrying the S4<sup>3</sup>, and even dimeric “two-pore” K2P channels such as human K2P1<sup>4</sup>. Mammalian Nav and Cav channel  $\alpha$  subunits consist of four repeats of the 6-TM module whereas mammalian Kv channels form as a tetramer of four non-covalently bound 6-TM  $\alpha$  subunits (Figure 1A).

In Kvs, Navs and Cavs, the voltage sensor is attached to the channel “gate” and when the voltage sensor senses a change in membrane potential and moves in response to this, the movement is communicated to the gate to open or close the pore depending on the channel

type; all three channel types are opened by membrane depolarization<sup>1</sup>. Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels are activated (opened) by membrane hyperpolarization; these channels pass both Na<sup>+</sup> and K<sup>+</sup> and are referred to as pacemaker channels because they trigger subsequent action potentials in response to undershoot from the previous action potential, and are essential for controlling the heart beat and some rhythmic neuronal firing<sup>5</sup>.

Of all the known Kv channel  $\alpha$  subunits, only one, KCNQ1, has thus far been discovered to have the ability to ostensibly lose its voltage dependence. KCNQ1 co-assembles with members of the KCNE family of single transmembrane segment K<sup>+</sup> ion channel ancillary or  $\beta$  subunits (Figure 1A–C) to enable it to juggle such contrasting roles as cardiac myocyte repolarization, and epithelial cell ion homeostasis/transporter regulation<sup>6</sup>. KCNQ1 exists as a tetramer of  $\alpha$  subunits in complexes with two KCNE1 subunits at the plasma membrane<sup>7–9</sup>, although stoichiometric variability (between 4:2 and 4:4,  $\alpha$ : $\beta$ ) has also been proposed<sup>10,11</sup> (Figure 1B). The stoichiometry of other Kv-KCNE complexes other than KCNQ1-KCNE1 has not been reported. Channels formed by KCNQ1 and KCNE1 - originally named slowly activating K<sup>+</sup> current (I<sub>sK</sub>)<sup>12</sup> and also referred to as Minimal K<sup>+</sup> channel (MinK)<sup>13</sup> - open very slowly, and less easily at negative voltages than homomeric KCNQ1 channels<sup>14,15</sup> (Figure 2). In sharp contrast, KCNE3 (originally named MinK-related peptide 2, MiRP2)<sup>16</sup> has even more striking effects, locking open the KCNQ1 S4 to almost entirely remove the voltage dependence of KCNQ1 activation, converting it to a K<sup>+</sup> leak channel<sup>17,18</sup>. This review covers the mechanisms and physiological roles of KCNE1 and KCNE3 regulation of KCNQ1 and other Kv channels. A recent companion review was focused on KCNE2<sup>19</sup>.

## KCNE1 and KCNE3 in the context of the KCNE gene family

The first-recognized member of the KCNE family, KCNE1 was discovered by expression cloning via injection of rat kidney mRNA into *Xenopus laevis* oocytes. One fraction of RNA generated a slowly activating, K<sup>+</sup>-selective and voltage-dependent current measurable by two-electrode voltage-clamp (TEVC) electrophysiology<sup>12</sup>. This finding initially caused confusion because the sequenced KCNE1 protein was much smaller than, and bore no sequence similarity to, the known Kv  $\alpha$  subunits<sup>20,21</sup>. The current generated by KCNE1 strongly resembled the mammalian cardiac Kv current known as I<sub>Ks</sub> (slow-activating K<sup>+</sup> current). Eight years after KCNE1 was cloned, KCNQ1 (then named KvLQT1, also referred to as Kv7.1) was positionally cloned via its linkage to inherited Long QT syndrome (LQTS), a defect in ventricular repolarization that can result from mutations in KCNQ1<sup>22</sup>. KCNQ1 was found, like KCNE1, to be expressed in human heart. Furthermore, *Xenopus laevis* KCNQ1 was found to be endogenously expressed in *Xenopus* oocytes. Co-expression of KCNQ1 and KCNE1 recapitulated the characteristics of I<sub>Ks</sub> in cells that, unlike *Xenopus* oocytes, do not express sufficient endogenous KCNQ1 to yield currents upon heterologous expression of KCNQ1 alone, i.e., Chinese Hamster ovary (CHO) cells. KCNE1 was thus recast as a regulatory, or  $\beta$ , subunit of KCNQ1<sup>14,15</sup>, and was swiftly discovered, like KCNQ1, to associate with LQTS<sup>23,24</sup>.

KCNE1 was a white elephant for a decade, until the discovery of its relatives using Basic Local Alignment Search Tool (BLAST) screening of online libraries of expressed sequence tags (ESTs)<sup>16</sup>. Although the five *KCNE* genes share relatively little similarity with one another, they each exhibit 1-TM topology with an extracellular N-terminal domain and intracellular C-terminal domain. In addition, each possesses a consensus protein kinase C (PKC) phosphorylation site in the membrane-proximal portion of the cytoplasmic C-terminal region<sup>19</sup>. BLAST searching with features of KCNE1 known to be important for its function circumvented the difficulties presented by relatively low family-wide sequence identity, and uncovered KCNE2, 3 and 4 – which we initially termed MinK-related peptides (MiRPs) 1, 2 and 3<sup>16</sup>. A fifth member, KCNE1L or KCNE5, was also discovered<sup>25</sup>.

## KCNE1 and KCNE3 regulation of KCNQ1

KCNQ1 is a highly versatile Kv  $\alpha$  subunit, which is regulated by a number of different types of protein to produce functionally distinct channel complexes<sup>6</sup>. All five of the KCNE proteins regulate KCNQ1 with distinct functional outcomes, and the effects of KCNE1 and KCNE3 are particularly striking. When heterologously co-expressed with KCNQ1 in mammalian cell lines such as Chinese Hamster ovary (CHO) or human embryonic kidney (HEK) cells, KCNE1 right-shifts the voltage dependence of KCNQ1 activation (opening), slows its activation 5–10 fold<sup>14,15</sup>, increases its unitary conductance 4-fold (as measured by noise variance analysis)<sup>26</sup>, slows its deactivation (closing) and eliminates its inactivation<sup>27</sup>. In sum, this increases KCNQ1 peak currents at positive voltages several-fold (Figure 2).

In contrast, KCNE3 holds open KCNQ1 such that the complex is constitutively active, no longer relying on membrane depolarization to open<sup>17</sup>. Instead, current magnitude (and direction) through KCNQ1-KCNE3 is dictated almost exclusively by driving force (Figure 2). Direct structural studies of the KCNE proteins in isolation (not complexed with  $\alpha$  subunits) revealed that the TM segment of KCNE1 is  $\alpha$ -helical, and that approximately half the KCNE1 extracellular domain adopts an  $\alpha$  helical conformation<sup>28–31</sup>. Despite relatively low sequence similarity with KCNE1, the secondary structure distributions of the KCNE3 TM and extracellular domains are quite similar to those of KCNE1<sup>32</sup>. A plethora of structure-function studies have been directed toward understanding the molecular bases for these differences, with The McDonald lab discovered a single residue in the TM region (T58 in KCNE1; V72 in KCNE3) that when switched between KCNE1 and KCNE3 could swap their activation properties. Thus, V72T-KCNE3 slows KCNQ1 activation almost as much as KCNE1 does, and eliminates KCNQ1-KCNE3 constitutive activation<sup>33</sup>. Conversely, T58V KCNE1 introduces half as much constitutive current as observed for KCNQ1-KCNE3, and increases the KCNQ1-KCNE1 activation rate 3-fold. Furthermore, concomitant introduction of two KCNE3 residues, to yield F57T, T58V-KCNE1, yielded KCNQ1-KCNE1 channels that were only twofold slower activating than KCNQ1-KCNE3 and almost matched its fractional constitutive current; these channels could be closed by holding for 3 s at  $-120$  mV instead of the normal  $-80$  mV<sup>33</sup>.

We subsequently found, using tryptophan tolerance scanning of KCNQ1 S6 followed by mutagenesis of the KCNE1 and KCNE3 residues identified by the McDonald lab, that KCNE1 T58 and L59 interact with KCNQ1 F339 and F340, whereas KCNE3 V72 interacts

with KCNQ1 S338<sup>34</sup>; of note, T58 and L59 mutants were among the first described in KCNE1-linked Jervell and Lange-Nielsen syndrome (JLNS), a cardioauditory syndrome comprising LQTS and sensorineural deafness<sup>13</sup> (see below). It should be noted that the McDonald lab study utilized the CHO cell expression system<sup>33</sup> whereas our study involved *Xenopus* oocytes. An interesting phenomenon of KCNQ1-KCNE3 channels is that they exhibit an almost perfectly linear current-voltage relationship when expressed in *Xenopus laevis* oocytes, while in the typical mammalian heterologous expression systems they exhibit some constitutive activation but a much less linear IV curve. The basis for this difference, be it an artifact of the different techniques used to record whole-cell currents in oocytes (two-electrode voltage clamp, TEVC) versus mammalian cells (patch clamp), or a difference in co-factor expression between the systems, has not to the author's knowledge been reported. While one may assume the mammalian cells are a truer representation of what might occur *in vivo* in mammalian tissues, the oocyte system more dramatically highlights the capabilities of KCNE3.

Other KCNE1 and KCNE3 residues are also important for maintaining their tight control of KCNQ1 activation, as uncovered in oocyte studies using TEVC. In KCNE1, the C-terminal domain appears to exert a strong influence on KCNQ1 activation, regulating channel assembly, destabilizing the KCNQ1 open state, altering deactivation rate and modulating rate-dependent facilitation of KCNQ1 activity<sup>35</sup>. The intracellular end of the KCNE1 transmembrane region is proposed to sit on the S5 end of the KCNQ1 S4-S5 linker (a portion of the channel that links the gate to the voltage sensor)<sup>30</sup>, and protein-protein interactions were detected between cysteines substituted for wild-type residues H363 (in the S6-proximal region of the KCNQ1 C-terminal domain) and H73, S74 and D76 in the KCNE1 C-terminal domain, and between residues H369 with D76<sup>36</sup> (Figure 3A). These interactions probably contribute strongly to slowing KCNQ1 activation and, notably, human KCNE1 S74L and D76N mutations are among the first-described, most-studied, and most pathogenic KCNE1 variants<sup>14</sup>. The membrane-proximal portion of the extracellular domain of KCNE1 (residues G40 in the activated state and K41 in the resting state) comes close to KCNQ1 S1 (I145, at the extracellular end), as evidenced from substituted cysteine disulfide trapping. Similarly, a cysteine substituted at KCNE1 L42 can be linked to V324C in KCNQ1 S6, with the result of eliminating deactivation. These interactions themselves might not necessarily be highly influential in the gating of wild-type KCNQ1-KCNE1 complexes but they suggest how KCNE1 orientation might change with respect to KCNQ1 during gating<sup>37,38</sup> (Figure 3A).

In contrast, in KCNE3, the transmembrane domain appears to override the influence of its C-terminal domain<sup>39</sup>. In addition, The KCNE3 N-terminal region possesses two acidic residues crucial for the robust constitutive current exhibited by KCNQ1-KCNE3 channels when expressed in oocytes. Using double-mutant thermodynamic cycle analysis, we discovered energetic coupling of KCNE3 residues D54 and D55 specifically to residue R237 in the voltage-sensing S4 helix of KCNQ1<sup>40</sup>. We had previously found that the relative charge paucity of KCNQ1 S4 (+3, the lowest of all known eukaryotic voltage-dependent ion channels) was instrumental in the functional flexibility of KCNQ1 in terms of regulation by KCNE subunits<sup>18</sup>. Neutralization of R231 within KCNQ1 S4, by replacement with alanine, converts KCNQ1 to a K<sup>+</sup> leak channel in the absence of KCNEs, and the same is achieved in

related  $\alpha$  subunit KCNQ4 by a triple mutation that mimics the charge balance of R231A-KCNQ1<sup>18,41</sup>. Homomeric R237A-KCNQ1 channels exhibit slightly right-shifted activation voltage dependence compared to homomeric KCNQ1, but the former accumulate in the open state with repetitive membrane depolarizations, deactivating very slowly upon repolarization<sup>18</sup>. In KCNQ1-KCNE3 complexes, KCNQ1-R237 appears to engage in electrostatic interactions with KCNE3 D54 and D55 to help stabilize the KCNQ1 S4, and therefore also the pore, in the activated state, even at negative voltages (deactivation can be seen to occur over several seconds when hyperpolarizing to  $-120$  mV) (Figure 3A). Interestingly, KCNE3 D54 partially protects KCNQ1-KCNE3 channels from the inhibitory effects of loss of plasma membrane phospholipid head groups. Normally, these negatively charged phosphocholines stabilize the activated conformation of S4, facilitating voltage-dependent activation. Removal of these head groups via hydrolysis by, for example, sphingomyelinase C, inhibits activity of channels including Kv2.1<sup>42</sup> and KCNQ1, but KCNE3 (and not KCNE1) helps maintain KCNQ1 activity in the face of sphingomyelinase C because KCNE3-D54 mimics the S4-stabilizing action of membrane phosphocholines<sup>40</sup>.

As striking as the constitutive activation of KCNQ1 endowed by KCNE3, is the laboriously slow activation endowed by KCNE1. As covered above, the KCNE1 C-terminal domain and to some extent the transmembrane domain may be important in slowing KCNQ1 activation, but is this achieved by slowing the voltage sensor, the pore opening, or both? There are at least two camps in terms of this aspect of the mechanistic underpinnings of slow KCNQ1-KCNE1 activation. The Goldstein and Bezanilla labs approached the problem using cut-open oocyte recording, a technique that permits much better voltage clamp and improved time resolution compared to conventional TEVC, facilitating measurement of gating currents – the current generated from movement of the charged voltage sensor itself. The cut-open oocyte recordings were combined with site-directed fluorimetry to also monitor voltage sensor movement by a complementary approach. They discovered that unlike homomeric KCNQ1, during KCNQ1-KCNE1 activation S4 moves too slowly to permit resolution of the gating current; by fluorimetry S4 was found to move 30-fold slower than that of the oft-studied Shaker Kv channel<sup>43</sup>.

Nakajo and Kubo found, using methanethiosulfonate (MTS) modification of cysteine-substituted KCNQ1 residues, that accessibility of A226C-KCNQ1, a substituted residue near the extracellular side of KCNQ1 S4, was 13-fold slower when KCNE1 was co-expressed compared to KCNQ1 alone. In contrast, when KCNE3 was co-expressed, KCNQ1 A226C accessibility was voltage-independent. This is consistent with the slow S4 movement model for KCNQ1-KCNE1 activation, although it is also consistent with S4 equilibrium rather than speed of movement being modulated by KCNE1<sup>44</sup>. Subsequent work by Nakajo and Kubo also suggested KCNE1 modulates interactions between S4 and S5 to affect activation gating, which could affect S4 movement speed and/or coupling of S4 to the channel gate<sup>45</sup>. The Seeböhm lab found that KCNE1 interacts with both S4 and S5/S6 to form what is probably a stable pre-open state that may slow activation<sup>46</sup>. Utilizing voltage clamp fluorimetry of *Xenopus* oocyte-expressed channels, the Kass lab formulated a dual-effect model for KCNE1 regulation of KCNQ1, in which KCNQ1 can open after activation of just one S4, while KCNQ1-KCNE1 needs all four S4s to shift before the pore opens. This model incorporates both slow S4 movement, and the need for all four S4s to open, as the basis of



slow KCNQ1-KCNE1 activation<sup>47,48</sup>. The Fedida lab found using single channel analysis that KCNQ1-KCNE1 flits between a variety of subconductance states, behavior that may or may not also exist in faster channels but could be too rapid to resolve in these cases, and may strongly influence opening and closing rates of KCNQ1-KCNE1<sup>49</sup>.

The jury is clearly still out over the specifics, but in general terms it appears KCNE1 interaction with S4 retards KCNQ1-KCNE1 activation, directly and/or via altered interaction with S4 and S5/S6. Discrepancies between different studies could arise from different preparations, protocols and interpretations. Interaction of KCNE1 with KCNQ1 S4 may also generate the right-shift in voltage dependence of activation induced by KCNE1, possibly by altering the manner in which S4 senses the stabilizing acidic residues in other, nearby KCNQ1 TM domains<sup>46,50,51</sup>.

Low mobility of the KCNE1-bound KCNQ1 S4 was also recently suggested to underlie the slow deactivation conferred by KCNE1<sup>52</sup>. In this comprehensive combination of experimental work, and modeling using elastic network analysis, loss of KCNQ1 C-type (slow) inactivation, another change conferred by KCNE1 co-assembly, was assessed in the context of acidic residues that influence slow inactivation of KcsA (the *Streptomyces lividans* K<sup>+</sup> channel used by the McKinnon lab to produce the first high-resolution K<sup>+</sup> channel structure<sup>2</sup>). It was suggested that KCNE1 limits positional fluctuations in the KCNQ1 outer vestibule and selectivity filter that drive slow inactivation, thereby eliminating or at least dampening the inactivation process. Finally, the increased conduction of KCNQ1 upon KCNE1 co-assembly was attributed in this study to a shift in KCNQ1 residues G272, V310 and T311 such that they move in concert with an entire “dynamic domain” in the pore. This is proposed to increase the scale of pore movement and therefore increase conductance, and is consistent with the results of previous mutagenesis studies<sup>52</sup>. The contrasting mechanisms by which KCNE1 and KCNE3 exert their effects on KCNQ1 gating and conductance, and possible locations of KCNE1 and KCNE3 within complexes with KCNQ1, are summarized in Figure 3A and B.

In addition, KCNE1 modulates KCNQ1 internalization from the plasma membrane. While KCNQ1 channels can be internalized by Nedd4/Nedd4-like- and Rab5-dependent processes with or without KCNE1 co-assembly<sup>53,54</sup>, KCNE1 mediates an alternative process, clathrin-mediated endocytosis of KCNQ1<sup>55</sup>. This dynamin-dependent process is enhanced by PKC phosphorylation of KCNE1 at residue S103<sup>56</sup>, explaining previous findings that S102 phosphorylation diminished currents generated by KCNE1 (in complex with endogenous KCNQ1) in *Xenopus* oocytes<sup>57,58</sup>.

KCNE1 and KCNE3 also exhibit contrasting effects on the functional outcomes of KCNQ1 regulation by other factors. Serine 27 in the KCNQ1 N-terminal region can be phosphorylated by protein kinase A (PKA), a physiologically important mechanism for  $\beta$ -adrenergic stimulation of cardiac  $I_{Ks}$ . Although S27 can be phosphorylated regardless of the co-expressed KCNE isoform, the functional effect also requires KCNE1 (or KCNE2) and the cytoplasmic protein yotiao in the complex, despite the PKA site being on KCNQ1 itself. KCNQ1-KCNE3 complexes do not show the same upregulation in response to PKA phosphorylation of KCNQ1 S27<sup>59</sup>. Of note, KCNE1 increases the sensitivity of KCNQ1



channels to phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>), a plasma membrane lipid that acts as a co-factor for a variety of ion channels and augments  $I_{Ks}$ . It is not yet known whether KCNE3 has similar effects, but all members of the KCNE family possess similar residues to those important for modifying the manner in which PIP<sub>2</sub> interacts with KCNQ1<sup>60</sup>.

## KCNE1 and KCNE3 regulation of other Kv $\alpha$ subunits

Although KCNE1 and KCNE3 regulation of other Kv channels is not generally as well understood as their effects on KCNQ1, it is interesting to note that their regulation of other  $\alpha$  subunits also typically results in disparate outcomes (Table 1). The first non-KCNQ1  $\alpha$  subunit found to be regulated by KCNE1 was the human ether-a-go-go related gene product (hERG, also termed Kv11.1 or KCNH2), the channel primarily responsible for driving human ventricular repolarization, especially at resting heart rates. KCNE1 increases hERG current density by a still unresolved mechanism in heterologous expression studies<sup>61</sup>, and probably regulates hERG in the heart<sup>62–64</sup>. In contrast, KCNE3 strongly inhibits hERG, again by an unresolved mechanism<sup>17</sup>, although the same KCNE3 substitution (R83H) that disrupts ability to constitutively open KCNQ1 channels and augment Kv3.4 currents<sup>65</sup> also blunts the ability of KCNE3 to inhibit hERG<sup>66</sup>. Interestingly, KCNE1 and KCNE3 are reported to form tripartite complexes with Kv12.2 (also termed ELK2 or KCNH3), inhibiting its surface expression and activation in *Xenopus* oocytes; this may also occur in mouse brain<sup>67</sup>.

KCNE1 and KCNE3 both slow Kv2.1 activation and deactivation, possibly increasing the diversity of Kv2.1 currents in heart and brain<sup>64,68</sup>, and one of the rare instances in which these two KCNEs exhibit comparable effects on the activity of a specific Kv channel. In contrast, KCNE1 and KCNE3 have opposite effects on Kv3.4, a rapidly inactivating, N-type  $\alpha$  subunit important in skeletal muscle and the CNS – albeit by different mechanisms. KCNE1 robustly inhibits Kv3.4 activity by retaining it early in the secretory pathway (endoplasmic reticulum and/or Golgi apparatus). We discovered that this provides a mechanism by which cells can ensure only mixed N-type/delayed rectifier channel complexes with intermediate inactivation kinetics, and not homomeric N-type  $\alpha$  subunit channels, reach the plasma membrane. Both KCNE1 and KCNE2 exhibit this retention ability, and they can retain all three classic N-type, inactivation domain-containing Kv  $\alpha$  subunits (Kv1.4, Kv3.3 and Kv3.4) until rescue by same-subfamily delayed rectifiers<sup>69,70</sup>. Conversely, KCNE3 augments activity of Kv3.4 channels, by a mechanism involving left-shifted voltage dependence of activation, increased unitary conductance, accelerated recovery from inactivation, and suppression of cumulative inactivation<sup>65</sup>. With respect to regulation of Kv3.1, Kv3.2, and Kv3.1-Kv3.2 heteromers, KCNE1 and KCNE3 both slow activation and deactivation and accelerate inactivation, but the effects of KCNE1 are of much greater magnitude<sup>71</sup>.

KCNE3 was recently found to inhibit Kv4.2, and Kv4.2-KCNE3 complexes may contribute to spike frequency and other properties in auditory neurons<sup>72</sup> (see below), while no effects were observed for KCNE1 with Kv4.2 in *Xenopus* oocyte co-expression studies (albeit using a staggered,  $\alpha$  subunit-first, cRNA injection protocol)<sup>73</sup>. Further, KCNE3 was found to inhibit Kv4.3 (fourfold reduction in current density) in CHO cells<sup>74</sup>, while in contrast, in

HEK cells KCNE1 augmented Kv4.3 current density fivefold and slowed its inactivation<sup>75</sup>. Association of the cytosolic ancillary subunit, KChIP2, altered these effects. Thus, in tripartite complexes, all KCNEs accelerated activation and inactivation of Kv4.3-KChIP2 channel complexes, although compared to complexes formed with KCNE1, Kv4.3-KChIP2-KCNE3 channels exhibited lower current density, and slightly more negative half-maximal voltage dependence of steady-state activation and inactivation<sup>76</sup>. One or more of the KCNE subunits may thus contribute to functional diversity of cardiac  $I_{to}$ .

Returning to the KCNQ family, in both *Xenopus* oocytes and HEK cells, KCNE1 reportedly slows the activation of KCNQ5, decreases its inward rectification at highly depolarized voltages, and increases its peak current; conversely, KCNE3 inhibits KCNQ5<sup>77</sup>. Similarly, KCNE1 appears to mildly augment KCNQ4 current when co-expressed in *Xenopus* oocytes, whereas KCNE3 strongly inhibits KCNQ4 in this expression system<sup>17,78</sup>.

KCNE1, KCNE2 and KCNE3 show sex-dependent differences in expression that arise from hormonal influence and determine some sex-specific aspects of mammalian physiology. Cardiac KCNE2 expression is upregulated by estrogen via a direct genomic mechanism<sup>79</sup>. KCNE1 and KCNE3 (but not KCNE2) are expressed in rat colonic crypts and highly enriched in male versus female rodents; during the estrus cycle, colonic expression of KCNE3 (and colonic partner KCNQ1) fluctuates in a manner consistent with KCNE3 downregulation by estrogen, via PKC phosphorylation of KCNE3 serine 82. In heterologous expression experiments, estrogen inhibited KCNQ1-KCNE3 activity, but not that of KCNQ1-KCNE1<sup>80-82</sup>.

In contrast, KCNE1, 3 and 5 expression is upregulated in concert with that of the orphan nuclear receptor, estrogen-related receptor  $\gamma$  (ERR $\gamma$ ), in human syncytiotrophoblasts, and is downregulated by hypoxia; KCNE4 displays the reverse pattern. KCNE1 and KCNE3 expression in trophoblast cells is downregulated by shRNA suppression of ERR $\gamma$  and KCNE1 contains a putative ERR $\gamma$  response element within its 5' flanking region<sup>83</sup>. KCNE1 and KCNE2 expression was also found to be downregulated in ERR $\gamma$  null mouse hearts, a similar effect was observed for KCNE2 in parietal cells, and KCNE2 (like KCNE1) was found to contain a ERR $\gamma$  responsive element that binds ERR $\gamma$ <sup>84</sup>.

### Physiological roles for KCNE1: the heart and inner ear

The best-understood physiological roles for KCNE1 are encapsulated by JLNS, an inherited cardioauditory syndrome that results from severe disruption of KCNQ1-KCNE1 channels such as occurs with biallelic mutations in human *KCNE1* or *KCNQ1*<sup>23,85</sup>. The cardiac element of JLNS is LQTS, caused by loss of function of ventricular KCNQ1-KCNE1 channels, eroding the repolarization reserve of ventricular myocytes and delaying ventricular repolarization. Thus, the slow- and relatively positive membrane potential-activating KCNQ1-KCNE1 channel, which generates  $I_{Ks}$ , is important for repolarizing human ventricular myocytes to end their action potential in readiness for the next heartbeat<sup>24,86</sup>.  $I_{Ks}$  appears to be most important during physical exertion or other contexts when  $\beta$ -adrenergic stimulation increases  $I_{Ks}$  density to compensate for higher heart rates. At other times,  $I_{Kr}$

(generated by hERG, which is regulated *in vivo* by KCNE1 and KCNE2) is probably dominant in human ventricles<sup>87,88</sup>.

*KCNE1* mutants more commonly cause the LQT5 form of LQTS, without overt auditory symptoms, and presumably through disruption of  $I_{Ks}$  complex function, although these mutants can also cause loss-of-function of hERG-KCNE1 channels and therefore potentially ventricular  $I_{Kr}$  *in vivo*<sup>89</sup>. To the author's knowledge, *KCNE1* sequence variation has not been linked to Brugada syndrome or to Short QT syndrome (SQTS), either of which (opposite to LQTS) can result from gain of function in ventricular Kv channels<sup>90,91</sup>. However, a *KCNQ1* mutation was recently discovered that appears to shorten the QT interval by impairing association of KCNQ1 with KCNE1, leading to accelerated activation and a negative shift in the voltage dependence of activation of  $I_{Ks}$ ; the mutation also decreased inactivation of homomeric KCNQ1<sup>92</sup>. Human *KCNE1* sequence variants in its extracellular portion are associated with the relatively rare, idiopathic form of atrial fibrillation (AF), with the underlying mechanism considered to be gain of function of atrial myocyte KCNQ1-KCNE1 channels. In addition, a more common KCNE1 polymorphism, S38G, has been linked to altered predisposition to AF and LQTS, with environmental and other genetic factors influencing this predisposition<sup>93-96</sup>. The same polymorphism influences predisposition to postoperative atrial fibrillation<sup>97</sup>, a prevalent arrhythmia following cardiothoracic surgery, and KCNE1 is downregulated in the atria of pigs following lung lobectomy<sup>98</sup>. Human *KCNE1* sequence variants associated with human disease are summarized in Table 2.

While KCNQ1-KCNE1 channels activate much faster at body temperature than the classic slow activation they exhibit at room temperature<sup>99</sup> - which makes the effects of KCNE1 particularly apparent - KCNE1 induces other changes in KCNQ1 important for their function together in the heart. As explained above, KCNE1 (together with a raft of cytosolic regulatory proteins) facilitates PKA upregulation of  $I_{Ks}$  in response to  $\beta$  adrenergic stimulation<sup>100-105</sup>. KCNE1 also appears to prime KCNQ1 to be ready to respond to the need for elevated heart rate by inducing a reserve of near-open closed states prepared for rapid activation when needed<sup>87</sup>, such that  $I_{Ks}$  complexes can be thought of as the ventricles' 'minutemen'. As explained earlier, KCNE1 mediates PKC-stimulated endocytosis of KCNQ1-KCNE1 channels, providing an alternate pathway for downregulation of  $I_{Ks}$  (and also perhaps a therapeutic window for counteracting QT prolongation, if this process can be disrupted)<sup>56</sup>. Finally, elimination of KCNQ1 slow inactivation by KCNE1 may also better enable  $I_{Ks}$  to sustain rapid heart rates without current diminishment.

The non-inactivating status endowed by KCNE1 may also facilitate the established function of KCNQ1-KCNE1 in the inner ear. Although KCNQ1-KCNE1 channels activate voltage-dependently, they are capable of sustained activity at the membrane potentials typical for the apical membrane of strial marginal cells and dark cells of the inner ear (0 to +10 mV). KCNQ1-KCNE1 provides a conduit for  $K^+$  secretion, thus recycling  $K^+$  in the endolymph of the inner ear. In the human ear, loss of this recycling is sufficient to cause bilateral sensorineural deafness; *Kcnq1* deletion in mice revealed that this is associated with morphological abnormalities because of reduction in the volume of endolymph<sup>106</sup>. KCNQ1-KCNE1 channels are, in contrast, not prominent in adult murine ventricular function. Neonatal murine neonatal myocytes exhibit  $I_{Ks}$  and expression of both KCNQ1 and KCNE1

proteins<sup>56,89,107</sup>. Adult mouse ventricles express an adrenergic-sensitive steady-state current that is disrupted by *Kcnq1* deletion, does not involve KCNE1<sup>108</sup>, and could potentially be generated by KCNQ1-KCNE2 complexes. *Kcne1* deletion reportedly causes atrial fibrillation in mice, and KCNE1 can be detected in adult mouse atria and conduction system<sup>109</sup>, but it is not known which  $\alpha$  subunit(s) KCNE1 regulates in these tissues in the mouse – Kv2.1 being one possibility.

## Controversies and discrepancies (I). KCNE1 in the brain and kidneys

Typically not considered a neuronal complex, it was recently proposed that KCNQ1-KCNE1 channels may operate in some neurons, and that this could introduce a neural component to cardiac arrhythmias. Thus, mutations in KCNE1 or KCNQ1 might cause seizures that in turn trigger cardiac arrhythmias (perhaps exacerbated by the channels also being dysfunctional in the heart and therefore increasing arrhythmia susceptibility in the face of a trigger)<sup>110</sup>. Interestingly, *Kcnq1*<sup>-/-</sup> mouse hearts exhibit impaired repolarization *in vivo* but not when isolated, suggesting *Kcnq1*-linked LQTS in mice arises from an extracardiac source<sup>106</sup>. The controversy continues, centering on whether KCNE1 and KCNQ1 are actually expressed in neurons in mice and people.

*Kcne1*<sup>-/-</sup> mice exhibit altered salt and glucose homeostasis, and reduced NaCl consumption – the latter suggestive of a role for KCNE1 in mouse kidneys or salivary glands<sup>111</sup>. KCNQ1 and KCNE1 are expressed in mouse kidneys but they do not necessarily form a channel there, and the pharmacology and gating kinetics of K<sup>+</sup> currents in proximal convoluted tubule epithelial cells – where KCNE1 is expressed – are not consistent with KCNQ1-KCNE1 properties. Counterintuitively, the KCNQ1-preferential antagonist, chromanol 293B, had similar functional effects in the proximal tubule to those of *Kcne1* deletion, but this may reflect nonspecific action of chromanol 293B at the dosage used (100  $\mu$ M). The cell-specific expression, biological functions and  $\alpha$  subunit partners of KCNE1 in the kidneys remain a matter of debate<sup>112–116</sup>. KCNE1 was also previously suggested to form channels with KCNQ1 in the airway epithelium, but it now appears much more likely that KCNQ1-KCNE3 complexes are expressed there instead (see below)<sup>117</sup>.

## Physiological roles for KCNE3: the gut, airway and auditory neurons

KCNE3 is best known for its regulation of KCNQ1 in the intestine. KCNQ1-KCNE3 are located on the basolateral membrane of colonic crypt cells. Their constitutive activation and lack of inactivation enable them to provide a K<sup>+</sup> recycling conduit that facilitates electrogenic intestinal Cl<sup>-</sup> secretion. All available evidence for the importance of this process is from the mouse, and specifically the *Kcne3*<sup>-/-</sup> mouse line, and there are currently no reported human disease associations linking KCNE3 (or KCNQ1) mutations to altered intestinal Cl<sup>-</sup> secretion<sup>17,118</sup>. As mentioned above, estrogen downregulates intestinal KCNE3 expression, causing the water retention that occurs in female mice during proestrus. As observed for the intestine, *Kcne3* deletion in mice also disrupts tracheal Cl<sup>-</sup> secretion, and basolateral KCNQ1-KCNE3 complexes are thought to be required for cAMP-stimulated Cl<sup>-</sup> secretion in the airway epithelium. KCNQ1-KCNE3 channels may also facilitate Na<sup>+</sup>

reabsorption in the airways of mice<sup>117</sup>. Again, data for the potential role of KCNQ1-KCNE3 in human airway epithelia are currently lacking.

In a different study of *Kcne3*<sup>-/-</sup> mice, a role for KCNE3 in auditory neurons was uncovered. KCNE3 was found to be expressed in spiral ganglion neurons (SGNs), with *Kcne3*<sup>-/-</sup> SGNs utilized as a convincing negative control for expression. *Kcne3* deletion age-dependently altered the firing properties and membrane potential variability of SGNs, and resulted in an increase in the transient outward current in these cells. Kv4.2, and not Kv4.3, was found to be expressed in both apical and basal SGNs, where it co-localized with KCNE3. Accordingly, KCNE3 was found to diminish Kv4.2 activity when the two were co-expressed in CHO cells<sup>72</sup>. Therefore, KCNE3 may act as a dampener for Kv4.2 activity in SGNs, permitting dynamic regulation of the transient K<sup>+</sup> current in these cells without the cell being required to remove Kv4.2 from the membrane, which might be too slow for the cells' requirements or too energetically costly. The functional effects in SGNs of *Kcne3* deletion were only observed during onset of hearing, during the first 12 days. At day 56, only two effects could be observed in SGNs – slightly enhanced afterhyperpolarizations of basal but not apical SGNs, and reduced interspike interval. Thus, KCNE3 might be more important during development of hearing than after auditory maturity, or else compensatory remodeling of other channels might lessen the deleterious consequences of *Kcne3* deletion over time<sup>72</sup>.

## Controversies and discrepancies (II). KCNE3 in the brain, muscle and auditory system

We previously found expression of KCNE3 transcript by Northern blot in all regions tested of human brain, and by RT-PCR from 12 DIV cultured rat primary hippocampal neurons isolated from embryonic stage 18 Sprague Dawley rats<sup>68</sup>. In addition, we detected KCNE3 protein by western blot in crude membrane preparations isolated from adult Sprague Dawley rat whole brains. We detected KCNE3-Kv2.1 and KCNE3-Kv3.1 complexes in these preparations, using co-immunoprecipitations. Our studies showed that endogenous KCNE3 co-localized with endogenous Kv2.1 but not Kv3.1 in cultured hippocampal neurons, while siRNA knockdown of endogenous KCNE3 in the PC12 cell line upregulated endogenous PC12 cell delayed rectifier K<sup>+</sup> current. Heterologous co-expression studies in CHO cells were consistent with the functional effects we had observed by knocking down endogenous KCNE3 in PC12 cells, i.e., KCNE3 slowed the activation of and downregulated Kv2.1 current (and downregulated overall activity but reduced inactivation of Kv3.1b)<sup>68</sup>. As mentioned above, KCNE3 was detected by others in auditory neurons, with the added advantage of having a *Kcne3*<sup>-/-</sup> negative control<sup>72</sup>. However, in contrast to our findings, Preston *et al* reported a failure to detect KCNE3 in mouse brain<sup>118</sup>.

Similarly, Preston and colleagues reported a lack of KCNE3 expression in mouse skeletal muscle, and a lack of effects of *Kcne3* deletion on the skeletal muscle-related parameters they tested in mice: muscle morphology, spontaneous paralysis, myotonia, “movement”, and rotarod performance<sup>118</sup>. Our studies of KCNE3 in skeletal muscle were driven by the findings of colleagues that the human KCNE3 R83H mutation is associated with periodic

paralysis – a skeletal muscle disorder in which sufferers experience bouts of debilitating paralysis. We detected *KCNE3* transcript by northern blot in human skeletal muscle, and found KCNE3 protein in rat sartorius muscle by western blot and in the mouse C2C12 myoblast cell line by western blot and immunofluorescence<sup>65</sup>. We determined that KCNE3 co-assembles with and functionally regulates Kv3.4, an N-type Kv channel  $\alpha$  subunit known to be expressed in skeletal muscle, and that the R83H mutation in KCNE3, found to associate in individuals with periodic paralysis within two families, impaired function of Kv3.4-KCNE3 channels. Specifically, the mutant disrupted the ability of KCNE3 to left-shift the voltage dependence of Kv3.4 activation, leading to depolarization of resting membrane potential in skeletal myocytes<sup>65</sup>. We subsequently found that the R83H mutation also impairs the ability of KCNE3 to regulate other Kv channels<sup>66</sup>. Further, we found that the histidine introduced in this substitution makes Kv3.4-KCNE3 channels susceptible to block by protons, and could therefore make carriers particularly prone to impaired channel function during rest after exercise, when muscle pH drops drastically. Additionally, we showed that the neighboring residue, S82, is a serine phosphorylation site and that PKC phosphorylation of this residue is required for the left-shift in voltage dependence of Kv3.4 activation endowed by KCNE3<sup>119</sup>. However, the disease association has been highly controversial, with others finding the R83H sequence variant in unaffected individuals, raising the possibility that it is a benign polymorphism<sup>120</sup>. Another possibility is that carriers need another genetic ‘hit’ or specific environmental conditions to provoke paralysis<sup>121</sup>.

Another controversy surrounds the possible association of KCNE3 (and KCNE1) with Ménière’s disease – an inner ear disorder that manifests as tinnitus, periodic hearing loss, and spontaneous episodes of vertigo. Single nucleotide polymorphisms (SNPs) in *KCNE1* (112G/A, coding for the well-studied S38G polymorphism) and *KCNE3* (198T/C, a synonymous switch within the codon for F66) were found in one study to be enriched in Japanese Ménière’s cohorts compared to unaffected individuals<sup>122</sup>. However, in a study of Caucasians, *KCNE1* and *KCNE3* SNPs were not found to associate with Ménière’s<sup>123</sup>. Deep resequencing of KCNE3 in Caucasian people with chronic tinnitus failed to either support or disprove a link, with the authors concluding that more power was required<sup>124</sup>. While both genes are expressed in the auditory system (KCNE3 has been detected in auditory neurons, and all five KCNEs were detected in outer hair cells<sup>78</sup>), and KCNE1 is tightly associated with JLNS<sup>23,85</sup>, establishing a firm link between human *KCNE3* sequence variation and auditory dysfunction will require further population or linkage studies.

Finally, not so much a controversy or necessarily a discrepancy, KCNE3 has been detected in human heart<sup>104</sup> (although the relative expression levels of KCNEs varies depending on the study<sup>76,125</sup> and may be affected by the sex of the donors, which was not always reported) and mutations in human *KCNE3* that disrupt its ability to inhibit Kv4.3 channels in human ventricle are thought to cause some cases of Brugada syndrome<sup>74,126</sup>. Human *KCNE3* mutations that cause gain-of-function of KCNQ1-KCNE3 channels are associated with atrial fibrillation, also suggested to arise from altered atrial myocyte channel activity<sup>127</sup>. Human *KCNE3* sequence variants associated with human disease are summarized in Table 3.

*KCNE3* transcript was also detected in horse heart<sup>43</sup>. However, *Kcne3* was not detected in either the atria or ventricles of adult mice, by two different labs using different *Kcne3*<sup>-/-</sup>



mouse strains as negative controls<sup>118,128</sup>, and *Kcne3* deletion did not alter Kv currents in isolated ventricular myocytes<sup>128</sup>. Yet, *Kcne3* deletion predisposed to ventricular arrhythmogenesis in mice, lengthening the QT interval in older adults and predisposing to sustained ventricular tachycardias following ischemia/reperfusion<sup>128</sup>. The underlying mechanism is unprecedented, and involves hyperaldosteronism in *Kcne3*<sup>-/-</sup> mice associated with autoimmune attack on the adrenal glands. *Kcne3* is not expressed in mouse adrenals, but its deletion causes cytokines to be released that attract activated lymphocytes specifically to the adrenal glands. Administration of spironolactone, an aldosterone receptor antagonist, to *Kcne3*<sup>-/-</sup> mice ameliorated their QT prolongation and predisposition to ventricular tachycardia<sup>128</sup>. Two questions arise: first, what causes the adrenals in *Kcne3*<sup>-/-</sup> mice to release signals to attract activated B cells? Second, can this mechanism also be a component of human *KCNE3*-linked arrhythmogenesis? Resolution of these condundra will require further investigation.

## Conclusions

In many ways, KCNE1 and KCNE3 represent the yin and yang of Kv channel regulation because of the often opposite yet complementary outcomes of their co-assembly with Kv  $\alpha$  subunits. As more and more functional data emerge from studies of the KCNE family in expression systems and from mouse and human genetics studies, it becomes apparent that the KCNEs constitute a molecular toolkit that diversifies Kv channel functionality but also facilitates dynamic alteration of channel properties in response to other signaling elements – including membrane lipids, hormones, kinases and even larger membrane proteins such as solute transporters<sup>129</sup>. Their human disease associations will likely not be as common as those of the Kv  $\alpha$  subunits for a variety of reasons – although in LQTS, base-for-base they match up rather well to  $\alpha$  subunit genes in terms of population-wide contribution to pathogenicity<sup>130</sup>. Nevertheless, the phenotypes of *Kcne* null mice are fascinating and can inform us of their physiological roles and the consequences of their ablation (typically an altogether different lesion than a point mutation). Because KCNEs can alter Kv channel responses to native signals and also to pharmacological agents (in the context of both therapeutic targeting and side effects)<sup>11,16,130–133</sup>, it behooves us to consider their presence in Kv and other channel complexes in different tissues, cell types and life stages, as they may yet provide a crucial ally in tuning drug specificity and efficacy.

## Acknowledgments

This review and the corresponding Gene Wiki article are written as part of the Cardiac Gene Wiki Review series--a series resulting from a collaboration between the journal GENE, the Gene Wiki Initiative, and the BD2K initiative. The Cardiac Gene Wiki Initiative is supported by National Institutes of Health (GM089820 and GM114833). Additional support for Gene Wiki Reviews is provided by Elsevier, the publisher of GENE. G.W.A. is grateful for financial support from the National Institutes of Health (HL079275, DK41544 and GM115189).

## Abbreviations

<b>AV block</b>	atrioventricular block
<b>BLAST</b>	basic local alignment search tool
<b>cAMP</b>	<i>cyclic adenosine monophosphate</i>



<b>Cav channel</b>	voltage-gated calcium channel
<b>CHO</b>	Chinese Hamster ovary
<b>di</b>	drug-induced
<b>ERR<math>\gamma</math></b>	estrogen-related receptor $\gamma$
<b>EST</b>	expressed sequence tag
<b>fs</b>	frameshift
<b>HCN</b>	hyperpolarization-activated, cyclic nucleotide-gated
<b>HEK</b>	human embryonic kidney
<b><i>I<sub>Ks</sub>/I<sub>sK</sub></i></b>	slowly activating K <sup>+</sup> current
<b>JLNS</b>	Jervell and Lange-Nielsen syndrome
<b>KChIP</b>	K <sup>+</sup> channel interacting protein
<b>Kv channel</b>	voltage-gated potassium channel
<b>LQTS</b>	Long QT syndrome
<b>MiRP</b>	MinK-related peptide
<b>MTS</b>	methanethiosulfonate
<b>Nav channel</b>	voltage-gated sodium channel
<b>PIP<sub>2</sub></b>	phosphatidylinositol 4,5-bisphosphate
<b>PKA</b>	protein kinase A
<b>PKC</b>	protein kinase C
<b>QTc</b>	QT interval corrected for heart rate
<b>SGN</b>	spiral ganglion neuron
<b>SNP</b>	single nucleotide polymorphism
<b>SQTS</b>	Short QT syndrome
<b>TdP</b>	torsade de pointes
<b>TEVC</b>	two-electrode voltage clamp
<b>TM</b>	transmembrane

## References

1. Catterall WA. Ion channel voltage sensors: structure, function, and pathophysiology. *Neuron*. 2010; 67(6):915–28. [PubMed: 20869590]

2. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R. The structure of the potassium channel: molecular basis of K<sup>+</sup> conduction and selectivity. *Science*. 1998; 280(5360):69–77. [PubMed: 9525859]
3. Long SB, Campbell EB, Mackinnon R. Crystal structure of a mammalian voltage-dependent Shaker family K<sup>+</sup> channel. *Science*. 2005; 309(5736):897–903. [PubMed: 16002581]
4. Miller AN, Long SB. Crystal structure of the human two-pore domain potassium channel K2P1. *Science*. 2012; 335(6067):432–6. [PubMed: 22282804]
5. Wahl-Schott C, Biel M. HCN channels: structure, cellular regulation and physiological function. *Cell Mol Life Sci*. 2009; 66(3):470–94. [PubMed: 18953682]
6. Abbott GW. Biology of the KCNQ1 potassium channel. *New Journal of Science*. 2014; 2014
7. Chen H, Kim LA, Rajan S, Xu S, Goldstein SA. Charybdotoxin binding in the I(Ks) pore demonstrates two MinK subunits in each channel complex. *Neuron*. 2003; 40(1):15–23. [PubMed: 14527430]
8. Plant LD, Xiong D, Dai H, Goldstein SA. Individual IKs channels at the surface of mammalian cells contain two KCNE1 accessory subunits. *Proc Natl Acad Sci U S A*. 2014
9. Wang KW, Goldstein SA. Subunit composition of minK potassium channels. *Neuron*. 1995; 14(6): 1303–9. [PubMed: 7605639]
10. Wang W, Xia J, Kass RS. MinK-KvLQT1 fusion proteins, evidence for multiple stoichiometries of the assembled IsK channel. *J Biol Chem*. 1998; 273(51):34069–74. [PubMed: 9852064]
11. Yu H, Lin Z, Mattmann ME, Zou B, Terrenoire C, Zhang H, Wu M, McManus OB, Kass RS, Lindsley CW, Hopkins CR, Li M. Dynamic subunit stoichiometry confers a progressive continuum of pharmacological sensitivity by KCNQ potassium channels. *Proc Natl Acad Sci U S A*. 2013; 110(21):8732–7. [PubMed: 23650380]
12. Takumi T, Ohkubo H, Nakanishi S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. *Science*. 1988; 242(4881):1042–5. [PubMed: 3194754]
13. Kaczmarek LK. Voltage-dependent potassium channels: minK and Shaker families. *New Biol*. 1991; 3(4):315–23. [PubMed: 2065015]
14. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. *Nature*. 1996; 384(6604):78–80. [PubMed: 8900282]
15. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. *Nature*. 1996; 384(6604):80–3. [PubMed: 8900283]
16. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. *Cell*. 1999; 97(2):175–87. [PubMed: 10219239]
17. Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, Greger R, Jentsch TJ. A constitutively open potassium channel formed by KCNQ1 and KCNE3. *Nature*. 2000; 403(6766):196–9. [PubMed: 10646604]
18. Panaghi G, Abbott GW. The role of S4 charges in voltage-dependent and voltage-independent KCNQ1 potassium channel complexes. *J Gen Physiol*. 2007; 129(2):121–33. [PubMed: 17227916]
19. Abbott GW. The KCNE2 K(+) channel regulatory subunit: Ubiquitous influence, complex pathobiology. *Gene*. 2015; 569(2):162–72. [PubMed: 26123744]
20. Papazian DM, Schwarz TL, Tempel BL, Jan YN, Jan LY. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from *Drosophila*. *Science*. 1987; 237(4816): 749–53. [PubMed: 2441470]
21. Tempel BL, Jan YN, Jan LY. Cloning of a probable potassium channel gene from mouse brain. *Nature*. 1988; 332(6167):837–9. [PubMed: 2451788]
22. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. *Nat Genet*. 1996; 12(1):17–23. [PubMed: 8528244]
23. Tyson J, Tranebjaerg L, Bellman S, Wren C, Taylor JF, Bathen J, Aslaksen B, Sorland SJ, Lund O, Malcolm S, Pembrey M, Bhattacharya S, Bitner-Glindzic M. IsK and KvLQT1: mutation in

- either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. *Hum Mol Genet.* 1997; 6(12):2179–85. [PubMed: 9328483]
24. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the *hminK* gene cause long QT syndrome and suppress IKs function. *Nat Genet.* 1997; 17(3):338–40. [PubMed: 9354802]
  25. Piccini M, Vitelli F, Seri M, Galletta LJ, Moran O, Bulfone A, Banfi S, Pober B, Renieri A. KCNE1-like gene is deleted in AMME contiguous gene syndrome: identification and characterization of the human and mouse homologs. *Genomics.* 1999; 60(3):251–7. [PubMed: 10493825]
  26. Sesti F, Goldstein SA. Single-channel characteristics of wild-type IKs channels and channels formed with two minK mutants that cause long QT syndrome. *J Gen Physiol.* 1998; 112(6):651–63. [PubMed: 9834138]
  27. Tristani-Firouzi M, Sanguinetti MC. Voltage-dependent inactivation of the human K<sup>+</sup> channel KvLQT1 is eliminated by association with minimal K<sup>+</sup> channel (minK) subunits. *J Physiol.* 1998; 510(Pt 1):37–45. [PubMed: 9625865]
  28. Mercer EA, Abbott GW, Ramesh B, Haris PI, Chapman D, Srari SK. Structural characterisation of a slowly activating potassium channel (IsK). *Biochem Soc Trans.* 1995; 23(3):478S. [PubMed: 8566375]
  29. Mercer EA, Abbott GW, Brazier SP, Ramesh B, Haris PI, Srari SK. Synthetic putative transmembrane region of minimal potassium channel protein (minK) adopts an alpha-helical conformation in phospholipid membranes. *Biochem J.* 1997; 325(Pt 2):475–9. [PubMed: 9230130]
  30. Kang C, Tian C, Sonnichsen FD, Smith JA, Meiler J, George AL Jr, Vanoye CG, Kim HJ, Sanders CR. Structure of KCNE1 and implications for how it modulates the KCNQ1 potassium channel. *Biochemistry.* 2008; 47(31):7999–8006. [PubMed: 18611041]
  31. Coey AT I, Sahu D, Gunasekera TS, Troxel KR, Hawn JM, Swartz MS, Wickenheiser MR, Reid RJ, Welch RC, Vanoye CG, Kang C, Sanders CR, Lorigan GA. Reconstitution of KCNE1 into lipid bilayers: comparing the structural, dynamic, and activity differences in micelle and vesicle environments. *Biochemistry.* 2011; 50(50):10851–9. [PubMed: 22085289]
  32. Kang C, Vanoye CG, Welch RC, Van Horn WD, Sanders CR. Functional delivery of a membrane protein into oocyte membranes using bicelles. *Biochemistry.* 2010; 49(4):653–5. [PubMed: 20044833]
  33. Melman YF, Krumerman A, McDonald TV. A single transmembrane site in the KCNE-encoded proteins controls the specificity of KvLQT1 channel gating. *J Biol Chem.* 2002; 277(28):25187–94. [PubMed: 11994278]
  34. Panaghie G, Tai KK, Abbott GW. Interaction of KCNE subunits with the KCNQ1 K<sup>+</sup> channel pore. *J Physiol.* 2006; 570(Pt 3):455–67. [PubMed: 16308347]
  35. Chen J, Zheng R, Melman YF, McDonald TV. Functional interactions between KCNE1 C-terminus and the KCNQ1 channel. *PLoS One.* 2009; 4(4):e5143. [PubMed: 19340287]
  36. Lvov A, Gage SD, Berrios VM, Kobertz WR. Identification of a protein-protein interaction between KCNE1 and the activation gate machinery of KCNQ1. *J Gen Physiol.* 2010; 135(6):607–18. [PubMed: 20479109]
  37. Chung DY, Chan PJ, Bankston JR, Yang L, Liu G, Marx SO, Karlin A, Kass RS. Location of KCNE1 relative to KCNQ1 in the I(KS) potassium channel by disulfide cross-linking of substituted cysteines. *Proc Natl Acad Sci U S A.* 2009; 106(3):743–8. [PubMed: 19131515]
  38. Xu X, Jiang M, Hsu KL, Zhang M, Tseng GN. KCNQ1 and KCNE1 in the IKs channel complex make state-dependent contacts in their extracellular domains. *J Gen Physiol.* 2008; 131(6):589–603. [PubMed: 18504315]
  39. Gage SD, Kobertz WR. KCNE3 truncation mutants reveal a bipartite modulation of KCNQ1 K<sup>+</sup> channels. *J Gen Physiol.* 2004; 124(6):759–71. [PubMed: 15572349]
  40. Choi E, Abbott GW. A shared mechanism for lipid- and beta-subunit-coordinated stabilization of the activated K<sup>+</sup> channel voltage sensor. *FASEB J.* 2010; 24(5):1518–24. [PubMed: 20040519]
  41. Panaghie G, Purtell K, Tai KK, Abbott GW. Voltage-dependent C-type inactivation in a constitutively open K<sup>+</sup> channel. *Biophys J.* 2008; 95(6):2759–78. [PubMed: 18567635]

42. Milesu M, Bosmans F, Lee S, Alabi AA, Kim JI, Swartz KJ. Interactions between lipids and voltage sensor paddles detected with tarantula toxins. *Nat Struct Mol Biol.* 2009; 16(10):1080–5. [PubMed: 19783984]
43. Ruscic KJ, Miceli F, Villalba-Galea CA, Dai H, Mishina Y, Bezanilla F, Goldstein SA. IKs channels open slowly because KCNE1 accessory subunits slow the movement of S4 voltage sensors in KCNQ1 pore-forming subunits. *Proc Natl Acad Sci U S A.* 2013; 110(7):E559–66. [PubMed: 23359697]
44. Nakajo K, Kubo Y. KCNE1 and KCNE3 stabilize and/or slow voltage sensing S4 segment of KCNQ1 channel. *J Gen Physiol.* 2007; 130(3):269–81. [PubMed: 17698596]
45. Nakajo K, Kubo Y. Steric hindrance between S4 and S5 of the KCNQ1/KCNE1 channel hampers pore opening. *Nat Commun.* 2014; 5:4100. [PubMed: 24920132]
46. Strutz-Seebohm N, Pusch M, Wolf S, Stoll R, Tapken D, Gerwert K, Attali B, Seebohm G. Structural basis of slow activation gating in the cardiac I<sub>Ks</sub> channel complex. *Cell Physiol Biochem.* 2011; 27(5):443–52. [PubMed: 21691061]
47. Osteen JD, Gonzalez C, Sampson KJ, Iyer V, Rebolledo S, Larsson HP, Kass RS. KCNE1 alters the voltage sensor movements necessary to open the KCNQ1 channel gate. *Proc Natl Acad Sci U S A.* 2010; 107(52):22710–5. [PubMed: 21149716]
48. Osteen JD, Barro-Soria R, Robey S, Sampson KJ, Kass RS, Larsson HP. Allosteric gating mechanism underlies the flexible gating of KCNQ1 potassium channels. *Proc Natl Acad Sci U S A.* 2012; 109(18):7103–8. [PubMed: 22509038]
49. Werry D, Eldstrom J, Wang Z, Fedida D. Single-channel basis for the slow activation of the repolarizing cardiac potassium current, I<sub>(Ks)</sub>. *Proc Natl Acad Sci U S A.* 2013; 110(11):E996–1005. [PubMed: 23431135]
50. Wu D, Delaloye K, Zaydman MA, Nekouzadeh A, Rudy Y, Cui J. State-dependent electrostatic interactions of S4 arginines with E1 in S2 during Kv7.1 activation. *J Gen Physiol.* 2010; 135(6):595–606. [PubMed: 20479111]
51. Wu D, Pan H, Delaloye K, Cui J. KCNE1 remodels the voltage sensor of Kv7.1 to modulate channel function. *Biophys J.* 2010; 99(11):3599–608. [PubMed: 21112284]
52. Gofman Y, Shats S, Attali B, Haliloglu T, Ben-Tal N. How does KCNE1 regulate the Kv7.1 potassium channel? Model-structure, mutations, and dynamics of the Kv7.1-KCNE1 complex. *Structure.* 2012; 20(8):1343–52. [PubMed: 22771213]
53. Seebohm G, Strutz-Seebohm N, Birkin R, Dell G, Bucci C, Spinosa MR, Baltaev R, Mack AF, Korniyuchuk G, Choudhury A, Marks D, Pagano RE, Attali B, Pfeufer A, Kass RS, Sanguinetti MC, Tavare JM, Lang F. Regulation of endocytic recycling of KCNQ1/KCNE1 potassium channels. *Circ Res.* 2007; 100(5):686–92. [PubMed: 17293474]
54. Jespersen T, Membrez M, Nicolas CS, Pitard B, Staub O, Olesen SP, Baro I, Abriel H. The KCNQ1 potassium channel is down-regulated by ubiquitylating enzymes of the Nedd4/Nedd4-like family. *Cardiovasc Res.* 2007; 74(1):64–74. [PubMed: 17289006]
55. Xu X V, Kanda A, Choi E, Panaghie G, Roepke TK, Gaeta SA, Christini DJ, Lerner DJ, Abbott GW. MinK-dependent internalization of the I<sub>Ks</sub> potassium channel. *Cardiovasc Res.* 2009; 82(3):430–8. [PubMed: 19202166]
56. Kanda VA, Purtell K, Abbott GW. Protein kinase C downregulates I<sub>(Ks)</sub> by stimulating KCNQ1-KCNE1 potassium channel endocytosis. *Heart Rhythm.* 2011; 8(10):1641–7. [PubMed: 21699843]
57. Varnum MD, Busch AE, Bond CT, Maylie J, Adelman JP. The min K channel underlies the cardiac potassium current I<sub>Ks</sub> and mediates species-specific responses to protein kinase C. *Proc Natl Acad Sci U S A.* 1993; 90(24):11528–32. [PubMed: 8265583]
58. Zhang ZJ, Jurkiewicz NK, Folander K, Lazarides E, Salata JJ, Swanson R. K<sup>+</sup> currents expressed from the guinea pig cardiac I<sub>sK</sub> protein are enhanced by activators of protein kinase C. *Proc Natl Acad Sci U S A.* 1994; 91(5):1766–70. [PubMed: 7510407]
59. Kurokawa J, Bankston JR, Kaihara A, Chen L, Furukawa T, Kass RS. KCNE variants reveal a critical role of the beta subunit carboxyl terminus in PKA-dependent regulation of the I<sub>Ks</sub> potassium channel. *Channels (Austin).* 2009; 3(1):16–24. [PubMed: 19077539]

60. Li Y, Zaydman MA, Wu D, Shi J, Guan M, Virgin-Downey B, Cui J. KCNE1 enhances phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) sensitivity of IKs to modulate channel activity. *Proc Natl Acad Sci U S A*. 2011; 108(22):9095–100. [PubMed: 21576493]
61. McDonald TV, Yu Z, Ming Z, Palma E, Meyers MB, Wang KW, Goldstein SA, Fishman GI. A minK-HERG complex regulates the cardiac potassium current I(Kr). *Nature*. 1997; 388(6639): 289–92. [PubMed: 9230439]
62. Anantharam A, Abbott GW. Does hERG coassemble with a beta subunit? Evidence for roles of MinK and MiRP1. *Novartis Found Symp*. 2005; 266:100–12. discussion 112–7, 155–8. [PubMed: 16050264]
63. Finley MR, Li Y, Hua F, Lillich J, Mitchell KE, Ganta S, Gilmour RF Jr, Freeman LC. Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart. *Am J Physiol Heart Circ Physiol*. 2002; 283(1):H126–38. [PubMed: 12063283]
64. McCrossan ZA, Roepke TK, Lewis A, Panaghie G, Abbott GW. Regulation of the Kv2.1 potassium channel by MinK and MiRP1. *J Membr Biol*. 2009; 228(1):1–14. [PubMed: 19219384]
65. Abbott GW, Butler MH, Bendahhou S, Dalakas MC, Ptacek LJ, Goldstein SA. MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. *Cell*. 2001; 104(2):217–31. [PubMed: 11207363]
66. Abbott GW, Goldstein SA. Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism. *FASEB J*. 2002; 16(3):390–400. [PubMed: 11874988]
67. Clancy SM, Chen B, Bertaso F, Mamet J, Jegla T. KCNE1 and KCNE3 beta-subunits regulate membrane surface expression of Kv12.2 K(+) channels in vitro and form a tripartite complex in vivo. *PLoS One*. 2009; 4(7):e6330. [PubMed: 19623261]
68. McCrossan ZA, Lewis A, Panaghie G, Jordan PN, Christini DJ, Lerner DJ, Abbott GW. MinK-related peptide 2 modulates Kv2.1 and Kv3.1 potassium channels in mammalian brain. *J Neurosci*. 2003; 23(22):8077–91. [PubMed: 12954870]
69. Kanda VA, Lewis A, Xu X, Abbott GW. KCNE1 and KCNE2 provide a checkpoint governing voltage-gated potassium channel alpha-subunit composition. *Biophys J*. 2011; 101(6):1364–75. [PubMed: 21943417]
70. Kanda VA, Lewis A, Xu X, Abbott GW. KCNE1 and KCNE2 inhibit forward trafficking of homomeric N-type voltage-gated potassium channels. *Biophys J*. 2011; 101(6):1354–63. [PubMed: 21943416]
71. Lewis A, McCrossan ZA, Abbott GW. MinK, MiRP1, and MiRP2 diversify Kv3.1 and Kv3.2 potassium channel gating. *J Biol Chem*. 2004; 279(9):7884–92. [PubMed: 14679187]
72. Wang W, Kim HJ, Lee JH, Wong V, Sihn CR, Lv P, Perez Flores MC, Mousavi-Nik A, Doyle KJ, Xu Y, Yamoah EN. Functional significance of K<sup>+</sup> channel beta-subunit KCNE3 in auditory neurons. *J Biol Chem*. 2014; 289(24):16802–13. [PubMed: 24727472]
73. Zhang M, Jiang M, Tseng GN. minK-related peptide 1 associates with Kv4.2 and modulates its gating function: potential role as beta subunit of cardiac transient outward channel? *Circ Res*. 2001; 88(10):1012–9. [PubMed: 11375270]
74. Delpon E, Cordeiro JM, Nunez L, Thomsen PE, Guerchicoff A, Pollevick GD, Wu Y, Kanters JK, Larsen CT, Hofman-Bang J, Burashnikov E, Christiansen M, Antzelevitch C. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. *Circ Arrhythm Electrophysiol*. 2008; 1(3):209–18. [PubMed: 19122847]
75. Deschenes I, Tomaselli GF. Modulation of Kv4.3 current by accessory subunits. *FEBS Lett*. 2002; 528(1–3):183–8. [PubMed: 12297301]
76. Radicke S, Cotella D, Graf EM, Banse U, Jost N, Varro A, Tseng GN, Ravens U, Wettwer E. Functional modulation of the transient outward current I<sub>to</sub> by KCNE beta-subunits and regional distribution in human non-failing and failing hearts. *Cardiovasc Res*. 2006; 71(4):695–703. [PubMed: 16876774]
77. Roura-Ferrer M, Etxebarria A, Sole L, Oliveras A, Comes N, Villarroel A, Felipe A. Functional implications of KCNE subunit expression for the Kv7.5 (KCNQ5) channel. *Cell Physiol Biochem*. 2009; 24(5–6):325–34. [PubMed: 19910673]

78. Strutz-Seebohm N, Seebohm G, Fedorenko O, Baltaev R, Engel J, Knirsch M, Lang F. Functional coassembly of KCNQ4 with KCNE-beta- subunits in *Xenopus* oocytes. *Cell Physiol Biochem*. 2006; 18(1–3):57–66. [PubMed: 16914890]
79. Kundu P, Ciobotaru A, Foroughi S, Toro L, Stefani E, Eghbali M. Hormonal regulation of cardiac KCNE2 gene expression. *Mol Cell Endocrinol*. 2008; 292(1–2):50–62. [PubMed: 18611433]
80. Alzamora R, O'Mahony F, Bustos V, Rapetti-Mauss R, Urbach V, Cid LP, Sepulveda FV, Harvey BJ. Sexual dimorphism and oestrogen regulation of KCNE3 expression modulates the functional properties of KCNQ1 K(+) channels. *J Physiol*. 2011; 589(Pt 21):5091–107. [PubMed: 21911611]
81. O'Mahony F, Thomas W, Harvey BJ. Novel female sex-dependent actions of oestrogen in the intestine. *J Physiol*. 2009; 587(Pt 21):5039–44. [PubMed: 19723780]
82. Rapetti-Mauss R, O'Mahony F, Sepulveda FV, Urbach V, Harvey BJ. Oestrogen promotes KCNQ1 potassium channel endocytosis and postendocytic trafficking in colonic epithelium. *J Physiol*. 2013; 591(Pt 11):2813–31. [PubMed: 23529131]
83. Luo Y, Kumar P, Mendelson CR. Estrogen-related receptor gamma (ERRgamma) regulates oxygen-dependent expression of voltage-gated potassium (K+) channels and tissue kallikrein during human trophoblast differentiation. *Mol Endocrinol*. 2013; 27(6):940–52. [PubMed: 23584901]
84. Alaynick WA, Way JM, Wilson SA, Benson WG, Pei L, Downes M, Yu R, Jonker JW, Holt JA, Rajpal DK, Li H, Stuart J, McPherson R, Remlinger KS, Chang CY, McDonnell DP, Evans RM, Billin AN. ERRgamma regulates cardiac, gastric, and renal potassium homeostasis. *Mol Endocrinol*. 2010; 24(2):299–309. [PubMed: 19965931]
85. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hordt M, Towbin JA, Borggrefe M, Assmann G, Qu X, Somberg JC, Breithardt G, Oberti C, Funke H. KCNE1 mutations cause jervell and Lange-Nielsen syndrome. *Nat Genet*. 1997; 17(3):267–8. [PubMed: 9354783]
86. Splawski I, Timothy KW, Vincent GM, Atkinson DL, Keating MT. Molecular basis of the long-QT syndrome associated with deafness. *N Engl J Med*. 1997; 336(22):1562–7. [PubMed: 9164812]
87. Silva J, Rudy Y. Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. *Circulation*. 2005; 112(10):1384–91. [PubMed: 16129795]
88. Suto F, Zhu W, Chan A, Gross GJ. IKr and IKs remodeling differentially affects QT interval prolongation and dynamic adaptation to heart rate acceleration in bradycardic rabbits. *Am J Physiol Heart Circ Physiol*. 2007; 292(4):H1782–8. [PubMed: 17142341]
89. Ohyama H, Kajita H, Omori K, Takumi T, Hiramoto N, Iwasaka T, Matsuda H. Inhibition of cardiac delayed rectifier K+ currents by an antisense oligodeoxynucleotide against IsK (minK) and over-expression of IsK mutant D77N in neonatal mouse hearts. *Pflugers Arch*. 2001; 442(3):329–35. [PubMed: 11484762]
90. Brugada, R.; Campuzano, O.; Brugada, P.; Brugada, J.; Hong, K. Brugada Syndrome. In: Pagon, RA., et al., editors. *Gene Reviews*. Seattle (WA): 1993.
91. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerschicoff A, Bianchi F, Giustetto C, Schimpf R, Brugada P, Antzelevitch C. Sudden death associated with short-QT syndrome linked to mutations in HERG. *Circulation*. 2004; 109(1):30–5. [PubMed: 14676148]
92. Moreno C, Oliveras A, de la Cruz A, Bartolucci C, Munoz C, Salar E, Gimeno JR, Severi S, Comes N, Felipe A, Gonzalez T, Lambiase P, Valenzuela C. A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. *Cardiovasc Res*. 2015
93. Ehrlich JR, Zicha S, Coutu P, Hebert TE, Nattel S. Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifier current and membrane localization. *Cardiovasc Res*. 2005; 67(3):520–8. [PubMed: 16039273]
94. Mao T, Miao HJ, Xu GJ, Gan TY, Zhou XH, Zhang J, Li FP, Tang BP. Association of single nucleotide polymorphism of KCNE1 and KCNE4 gene with atrial fibrillation in Xinjiang Uygur and Han population. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2013; 41(11):916–21. [PubMed: 24370217]



95. Olesen MS, Bentzen BH, Nielsen JB, Steffensen AB, David JP, Jabbari J, Jensen HK, Haunso S, Svendsen JH, Schmitt N. Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. *BMC Med Genet.* 2012; 13(1):24. [PubMed: 22471742]
96. Yao J, Ma Y, Xie X, Liu F, Chen B, An Y. Association of rs1805127 polymorphism of KCNE1 gene with atrial fibrillation in Uigur population of Xinjiang. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi.* 2011; 28(4):436–40. [PubMed: 21811988]
97. Voudris KV, Apostolakis S, Karyofyllis P, Doukas K, Zaravinos A, Androutopoulos VP, Michalis A, Voudris V, Spandidos DA. Genetic diversity of the KCNE1 gene and susceptibility to postoperative atrial fibrillation. *Am Heart J.* 2014; 167(2):274–280. e1. [PubMed: 24439990]
98. Heerdt PM, Kant R, Hu Z, Kanda VA, Christini DJ, Malhotra JK, Abbott GW. Transcriptomic analysis reveals atrial KCNE1 down-regulation following lung lobectomy. *J Mol Cell Cardiol.* 2012; 53(3):350–3. [PubMed: 22641150]
99. Dong MQ, Lau CP, Gao Z, Tseng GN, Li GR. Characterization of recombinant human cardiac KCNQ1/KCNE1 channels (I (K<sub>s</sub>)) stably expressed in HEK 293 cells. *J Membr Biol.* 2006; 210(3):183–92. [PubMed: 16909339]
100. Kurokawa J, Motoike HK, Rao J, Kass RS. Regulatory actions of the A-kinase anchoring protein Yotiao on a heart potassium channel downstream of PKA phosphorylation. *Proc Natl Acad Sci U S A.* 2004; 101(46):16374–8. [PubMed: 15528278]
101. Li Y, Chen L, Kass RS, Dessauer CW. The A-kinase anchoring protein Yotiao facilitates complex formation between adenylyl cyclase type 9 and the I<sub>Ks</sub> potassium channel in heart. *J Biol Chem.* 2012; 287(35):29815–24. [PubMed: 22778270]
102. Marx SO, Kurokawa J, Reiken S, Motoike H, D'Armiento J, Marks AR, Kass RS. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. *Science.* 2002; 295(5554):496–9. [PubMed: 11799244]
103. Nicolas CS, Park KH, El Harchi A, Camonis J, Kass RS, Escande D, Merot J, Loussouarn G, Le Bouffant F, Baro I. I<sub>Ks</sub> response to protein kinase A-dependent KCNQ1 phosphorylation requires direct interaction with microtubules. *Cardiovasc Res.* 2008; 79(3):427–35. [PubMed: 18390900]
104. Terrenoire C, Clancy CE, Cormier JW, Sampson KJ, Kass RS. Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. *Circ Res.* 2005; 96(5):e25–34. [PubMed: 15731462]
105. Terrenoire C, Houslay MD, Baillie GS, Kass RS. The cardiac I<sub>Ks</sub> potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. *J Biol Chem.* 2009; 284(14):9140–6. [PubMed: 19218243]
106. Casimiro MC, Knollmann BC, Ebert SN, Vary JC Jr, Greene AE, Franz MR, Grinberg A, Huang SP, Pfeifer K. Targeted disruption of the *Kcnq1* gene produces a mouse model of Jervell and Lange-Nielsen Syndrome. *Proc Natl Acad Sci U S A.* 2001; 98(5):2526–31. [PubMed: 11226272]
107. Knollmann BC, Casimiro MC, Katchman AN, Sirenko SG, Schober T, Rong Q, Pfeifer K, Ebert SN. Isoproterenol exacerbates a long QT phenotype in *Kcnq1*-deficient neonatal mice: possible roles for human-like *Kcnq1* isoform 1 and slow delayed rectifier K<sup>+</sup> current. *J Pharmacol Exp Ther.* 2004; 310(1):311–8. [PubMed: 15004216]
108. Knollmann BC, Sirenko S, Rong Q, Katchman AN, Casimiro M, Pfeifer K, Ebert SN. *Kcnq1* contributes to an adrenergic-sensitive steady-state K<sup>+</sup> current in mouse heart. *Biochem Biophys Res Commun.* 2007; 360(1):212–8. [PubMed: 17597584]
109. Temple J, Frias P, Rottman J, Yang T, Wu Y, Verheijck EE, Zhang W, Siprachanh C, Kanki H, Atkinson JB, King P, Anderson ME, Kupersmidt S, Roden DM. Atrial fibrillation in KCNE1-null mice. *Circ Res.* 2005; 97(1):62–9. [PubMed: 15947250]
110. Goldman AM, Glasscock E, Yoo J, Chen TT, Klassen TL, Noebels JL. Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death. *Sci Transl Med.* 2009; 1(2):2ra6.
111. Puchalski RB, Kelly E, Bachmanov AA, Brazier SP, Kuang J, Arrighi I, Barhanin J, Tordoff MG. NaCl consumption is attenuated in female KCNE1 null mutant mice. *Physiol Behav.* 2001; 74(3):267–76. [PubMed: 11714488]



112. Barriere H, Rubera I, Belfodil R, Tauc M, Tonnerieux N, Poujeol C, Barhanin J, Poujeol P. Swelling-activated chloride and potassium conductance in primary cultures of mouse proximal tubules. Implication of KCNE1 protein. *J Membr Biol.* 2003; 193(3):153–70. [PubMed: 12962276]
113. Millar ID, Hartley JA, Haigh C, Grace AA, White SJ, Kibble JD, Robson L. Volume regulation is defective in renal proximal tubule cells isolated from KCNE1 knockout mice. *Exp Physiol.* 2004; 89(2):173–80. [PubMed: 15123546]
114. Neal AM, Taylor HC, Millar ID, Kibble JD, White SJ, Robson L. Renal defects in KCNE1 knockout mice are mimicked by chromanol 293B in vivo: identification of a KCNE1-regulated K<sup>+</sup> conductance in the proximal tubule. *J Physiol.* 2011; 589(Pt 14):3595–609. [PubMed: 21576273]
115. Vallon V, Grahhammer F, Richter K, Bleich M, Lang F, Barhanin J, Volkl H, Warth R. Role of KCNE1-dependent K<sup>+</sup> fluxes in mouse proximal tubule. *J Am Soc Nephrol.* 2001; 12(10):2003–11. [PubMed: 11562398]
116. Vallon V, Grahhammer F, Volkl H, Sandu CD, Richter K, Rexhepaj R, Gerlach U, Rong Q, Pfeifer K, Lang F. KCNQ1-dependent transport in renal and gastrointestinal epithelia. *Proc Natl Acad Sci U S A.* 2005; 102(49):17864–9. [PubMed: 16314573]
117. Grahhammer F, Warth R, Barhanin J, Bleich M, Hug MJ. The small conductance K<sup>+</sup> channel, KCNQ1: expression, function, and subunit composition in murine trachea. *J Biol Chem.* 2001; 276(45):42268–75. [PubMed: 11527966]
118. Preston P, Wartosch L, Gunzel D, Fromm M, Kongsuphol P, Ousingsawat J, Kunzelmann K, Barhanin J, Warth R, Jentsch TJ. Disruption of the K<sup>+</sup> channel beta-subunit KCNE3 reveals an important role in intestinal and tracheal Cl<sup>-</sup> transport. *J Biol Chem.* 2010; 285(10):7165–75. [PubMed: 20051516]
119. Abbott GW, Butler MH, Goldstein SA. Phosphorylation and protonation of neighboring MiRP2 sites: function and pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis. *FASEB J.* 2006; 20(2):293–301. [PubMed: 16449802]
120. Sternberg D, Tabti N, Fournier E, Hainque B, Fontaine B. Lack of association of the potassium channel-associated peptide MiRP2-R83H variant with periodic paralysis. *Neurology.* 2003; 61(6):857–9. [PubMed: 14504341]
121. Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. *J Clin Endocrinol Metab.* 2002; 87(11):4881–4. [PubMed: 12414843]
122. Doi K, Sato T, Kuramasu T, Hibino H, Kitahara T, Horii A, Matsushiro N, Fuse Y, Kubo T. Meniere's disease is associated with single nucleotide polymorphisms in the human potassium channel genes, KCNE1 and KCNE3. *ORL J Otorhinolaryngol Relat Spec.* 2005; 67(5):289–93. [PubMed: 16374062]
123. Campbell CA, Della Santina CC, Meyer NC, Smith NB, Myrie OA, Stone EM, Fukushima K, Califano J, Carey JP, Hansen MR, Gantz BJ, Minor LB, Smith RJ. Polymorphisms in KCNE1 or KCNE3 are not associated with Meniere disease in the Caucasian population. *Am J Med Genet A.* 2010; 152A(1):67–74. [PubMed: 20034061]
124. Sand PG, Langguth B, Kleinjung T. Deep resequencing of the voltage-gated potassium channel subunit KCNE3 gene in chronic tinnitus. *Behav Brain Funct.* 2011; 7:39. [PubMed: 21899751]
125. Bendahhou S, Marionneau C, Haurogne K, Larroque MM, Derand R, Szuts V, Escande D, Demolombe S, Barhanin J. In vitro molecular interactions and distribution of KCNE family with KCNQ1 in the human heart. *Cardiovasc Res.* 2005; 67(3):529–38. [PubMed: 16039274]
126. Nakajima T, Wu J, Kaneko Y, Ashihara T, Ohno S, Irie T, Ding WG, Matsuura H, Kurabayashi M, Horie M. KCNE3 T4A as the genetic basis of Brugada-pattern electrocardiogram. *Circ J.* 2012; 76(12):2763–72. [PubMed: 22987075]
127. Lundby A, Ravn LS, Svendsen JH, Hauns S, Olesen SP, Schmitt N. KCNE3 mutation V17M identified in a patient with lone atrial fibrillation. *Cell Physiol Biochem.* 2008; 21(1–3):47–54. [PubMed: 18209471]
128. Hu Z, Crump SM, Anand M, Kant R, Levi R, Abbott GW. Kcne3 deletion initiates extracardiac arrhythmogenesis in mice. *FASEB J.* 2014; 28(2):935–45. [PubMed: 24225147]


129. Abbott GW, Tai KK, Neverisky DL, Hansler A, Hu Z, Roepke TK, Lerner DJ, Chen Q, Liu L, Zupan B, Toth M, Haynes R, Huang X, Demirbas D, Buccafusca R, Gross SS, Kanda VA, Berry GT. KCNQ1, KCNE2, and Na<sup>+</sup>-Coupled Solute Transporters Form Reciprocally Regulating Complexes That Affect Neuronal Excitability. *Sci Signal*. 2014; 7(315):ra22. [PubMed: 24595108]
130. Abbott GW. KCNE genetics and pharmacogenomics in cardiac arrhythmias: much ado about nothing? *Expert Rev Clin Pharmacol*. 2013; 6(1):49–60. [PubMed: 23272793]
131. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. *Proc Natl Acad Sci U S A*. 2000; 97(19):10613–8. [PubMed: 10984545]
132. Bett GC, Morales MJ, Beahm DL, Duffey ME, Rasmusson RL. Ancillary subunits and stimulation frequency determine the potency of chromanol 293B block of the KCNQ1 potassium channel. *J Physiol*. 2006; 576(Pt 3):755–67. [PubMed: 16887873]
133. Lerche C, Seebohm G, Wagner CI, Scherer CR, Dehmelt L, Abitbol I, Gerlach U, Brendel J, Attali B, Busch AE. Molecular impact of MinK on the enantiospecific block of I(Ks) by chromanols. *Br J Pharmacol*. 2000; 131(8):1503–6. [PubMed: 11139424]
134. Ohno S, Zankov DP, Yoshida H, Tsuji K, Makiyama T, Itoh H, Akao M, Hancox JC, Kita T, Horie M. N- and C-terminal KCNE1 mutations cause distinct phenotypes of long QT syndrome. *Heart Rhythm*. 2007; 4(3):332–40. [PubMed: 17341399]
135. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. *Heart Rhythm*. 2009; 6(9):1297–303. [PubMed: 19716085]
136. Shim SH, Ito M, Maher T, Milunsky A. Gene sequencing in neonates and infants with the long QT syndrome. *Genet Test*. 2005; 9(4):281–4. [PubMed: 16379539]
137. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. *Circulation*. 2000; 102(10):1178–85. [PubMed: 10973849]
138. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: a common cause of severe long-QT syndrome. *Circulation*. 2004; 109(15):1834–41. [PubMed: 15051636]
139. Fatini C, Sticchi E, Genuardi M, Sofi F, Gensini F, Gori AM, Lenti M, Michelucci A, Abbate R, Gensini GF. Analysis of minK and eNOS genes as candidate loci for predisposition to non-valvular atrial fibrillation. *Eur Heart J*. 2006; 27(14):1712–8. [PubMed: 16760206]
140. Xu LX, Yang WY, Zhang HQ, Tao ZH, Duan CC. Study on the correlation between CETP TaqIB, KCNE1 S38G and eNOS T-786C gene polymorphisms for predisposition and non-valvular atrial fibrillation. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2008; 29(5):486–92. [PubMed: 18956684]
141. Prystupa A, Dzida G, Myslinski W, Malaj G, Lorenc T. MinK gene polymorphism in the pathogenesis of lone atrial fibrillation. *Kardiol Pol*. 2006; 64(11):1205–11. discussion 1212–3. [PubMed: 17165161]
142. Husser D, Stridh M, Sornmo L, Roden DM, Darbar D, Bollmann A. A genotype-dependent intermediate ECG phenotype in patients with persistent lone atrial fibrillation genotype ECG-phenotype correlation in atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2009; 2(1):24–8. [PubMed: 19305639]
143. Li L, Shen C, Yao Z, Liang J, Huang C. Genetic Variants of Potassium Voltage-Gated Channel Genes (KCNQ1, KCNH2, and KCNE1) Affected the Risk of Atrial Fibrillation in Elderly Patients. *Genet Test Mol Biomarkers*. 2015; 19(7):359–65. [PubMed: 26066992]
144. Han HG, Wang HS, Yin Z, Jiang H, Fang M, Han J. KCNE1 112G>a polymorphism and atrial fibrillation risk: a meta-analysis. *Genet Mol Res*. 2014; 13(4):8367–77. [PubMed: 25366730]
145. Bianchi L, Shen Z, Dennis AT, Priori SG, Napolitano C, Ronchetti E, Bryskin R, Schwartz PJ, Brown AM. Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. *Hum Mol Genet*. 1999; 8(8):1499–507. [PubMed: 10400998]

146. Ma L, Lin C, Teng S, Chai Y, Bahring R, Vardanyan V, Li L, Pongs O, Hui R. Characterization of a novel Long QT syndrome mutation G52R-KCNE1 in a Chinese family. *Cardiovasc Res.* 2003; 59(3):612–9. [PubMed: 14499862]
147. Lai LP, Su YN, Hsieh FJ, Chiang FT, Juang JM, Liu YB, Ho YL, Chen WJ, Yeh SJ, Wang CC, Ko YL, Wu TJ, Ueng KC, Lei MH, Tsao HM, Chen SA, Lin TK, Wu MH, Lo HM, Huang SK, Lin JL. Denaturing high-performance liquid chromatography screening of the long QT syndrome-related cardiac sodium and potassium channel genes and identification of novel mutations and single nucleotide polymorphisms. *J Hum Genet.* 2005; 50(9):490–6. [PubMed: 16155735]
148. Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, Van Driest S, Karnes JH, Ingram C, Guo Y, Shyr Y, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis ER, Nickerson D, George AL Jr, Roden DM. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. *J Am Coll Cardiol.* 2014; 63(14):1430–7. [PubMed: 24561134]
149. Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome. *Circulation.* 1998; 97(2):142–6. [PubMed: 9445165]
150. Wu DM, Lai LP, Zhang M, Wang HL, Jiang M, Liu XS, Tseng GN. Characterization of an LQT5-related mutation in KCNE1, Y81C: implications for a role of KCNE1 cytoplasmic domain in IKs channel function. *Heart Rhythm.* 2006; 3(9):1031–40. [PubMed: 16945797]
151. Nielsen NH, Winkel BG, Kanters JK, Schmitt N, Hofman-Bang J, Jensen HS, Bentzen BH, Sigurd B, Larsen LA, Andersen PS, Haunso S, Kjeldsen K, Grunnet M, Christiansen M, Olesen SP. Mutations in the Kv1.5 channel gene KCNA5 in cardiac arrest patients. *Biochem Biophys Res Commun.* 2007; 354(3):776–82. [PubMed: 17266934]
152. Zeng ZY, Pu JL, Tan C, Teng SY, Chen JH, Su SY, Zhou XY, Zhang S, Li YS, Wang FZ, Gu DF. The association of single nucleotide polymorphism of slow delayed rectifier K<sup>+</sup> channel genes with atrial fibrillation in Han nationality Chinese. *Zhonghua Xin Xue Guan Bing Za Zhi.* 2005; 33(11):987–91. [PubMed: 16563243]
153. Zeng Z, Tan C, Teng S, Chen J, Su S, Zhou X, Wang F, Zhang S, Gu D, Makielski JC, Pu J. The single nucleotide polymorphisms of I(Ks) potassium channel genes and their association with atrial fibrillation in a Chinese population. *Cardiology.* 2007; 108(2):97–103. [PubMed: 17016049]
154. Porthan K, Marjamaa A, Viitasalo M, Vaananen H, Jula A, Toivonen L, Nieminen MS, Newton-Cheh C, Salomaa V, Kontula K, Oikarinen L. Relationship of common candidate gene variants to electrocardiographic T-wave peak to T-wave end interval and T-wave morphology parameters. *Heart Rhythm.* 2010; 7(7):898–903. [PubMed: 20215044]
155. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. *J Mol Med (Berl).* 2004; 82(3):182–8. [PubMed: 14760488]
156. Nishio Y, Makiyama T, Itoh H, Sakaguchi T, Ohno S, Gong YZ, Yamamoto S, Ozawa T, Ding WG, Toyoda F, Kawamura M, Akao M, Matsuura H, Kimura T, Kita T, Horie M. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. *J Am Coll Cardiol.* 2009; 54(9):812–9. [PubMed: 19695459]
157. Lin L, Horigome H, Nishigami N, Ohno S, Horie M, Sumazaki R. Drug-induced QT-interval prolongation and recurrent torsade de pointes in a child with heterotaxy syndrome and KCNE1 D85N polymorphism. *J Electrocardiol.* 2012; 45(6):770–3. [PubMed: 22999324]
158. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, Bezzina CR, Schulze-Bahr E, Guicheney P, Bishopric NH, Myerburg RJ, Schott JJ, Pfeufer A, Beckmann BM, Martens E, Zhang T, Stallmeyer B, Zumhagen S, Denjoy I, Bardai A, Van Gelder IC, Jamshidi Y, Dalageorgou C, Marshall V, Jeffery S, Shakir S, Camm AJ, Steinbeck G, Perz S, Lichtner P, Meitinger T, Peters A, Wichmann HE, Ingram C, Bradford Y, Carter S, Norris K, Ritchie MD, George AL Jr, Roden DM. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. *Circ Cardiovasc Genet.* 2012; 5(1):91–9. [PubMed: 22100668]

159. Gouas L, Nicaud V, Berthet M, Forhan A, Tiret L, Balkau B, Guicheney P. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. *Eur J Hum Genet.* 2005; 13(11):1213–22. [PubMed: 16132053]
160. Harmer SC, Wilson AJ, Aldridge R, Tinker A. Mechanisms of disease pathogenesis in long QT syndrome type 5. *Am J Physiol Cell Physiol.* 2010; 298(2):C263–73. [PubMed: 19907016]
161. Schulze-Bahr E, Schwarz M, Hauenschild S, Wedekind H, Funke H, Haverkamp W, Breithardt G, Pongs O, Isbrandt D. A novel long-QT 5 gene mutation in the C-terminus (V109I) is associated with a mild phenotype. *J Mol Med (Berl).* 2001; 79(9):504–9. [PubMed: 11692163]
162. Crump SM, Abbott GW. Arrhythmogenic KCNE gene variants: current knowledge and future challenges. *Front Genet.* 2014; 5:3. [PubMed: 24478792]
163. Ohno S, Toyoda F, Zankov DP, Yoshida H, Makiyama T, Tsuji K, Honda T, Obayashi K, Ueyama H, Shimizu W, Miyamoto Y, Kamakura S, Matsuura H, Kita T, Horie M. Novel KCNE3 mutation reduces repolarizing potassium current and associated with long QT syndrome. *Hum Mutat.* 2009; 30(4):557–63. [PubMed: 19306396]
164. Zhang DF, Liang B, Lin J, Liu B, Zhou QS, Yang YQ. KCNE3 R53H substitution in familial atrial fibrillation. *Chin Med J (Engl).* 2005; 118(20):1735–8. [PubMed: 16313760]

### Highlights

- KCNE1 and KCNE3 regulate K<sup>+</sup> channel gating, voltage dependence and trafficking
- KCNE1 and 3 often have opposite effects on channel function, especially so for KCNQ1
- KCNE1-KCNQ1 channels are best known for their role in cardiomyocyte repolarization
- KCNE3-KCNQ1 channels are important in various secretory epithelia
- Human *KCNE1* and *KCNE3* sequence variants cause various cardiac arrhythmias




**Figure 1. The KCNE gene family**

A. *Left*, Topology diagram of a 6TM spanning Kv  $\alpha$  subunit with voltage sensing domain (VSD) and pore domain highlighted. *Right*, 1TM topology of a KCNE subunit. Ext, extracellular; Int, intracellular.

B. 4:2  $\alpha$ : $\beta$  stoichiometry of a KCNQ1-KCNE1 complex.


C. Sequence alignment of the KCNE gene family. Transmembrane (TM) domain boxed; highly conserved residues/features indicated with gray shading.



**Figure 2. Functional effects of KCNE1 and KCNE3 on KCNQ1**

Example traces recorded by two-electrode voltage clamp from oocytes injected with cRNA encoding KCNQ1 alone or with KCNE1 or KCNE3. Voltage protocol shown at top. Scale bars: vertical, 2  $\mu$ A; horizontal, 1s. Dotted line indicates zero current level. Traces are from <sup>3</sup> and <sup>47</sup>.





**Figure 3. Mechanisms of KCNE1 and KCNE3 control of KCNQ1 gating and conductance**  
 A. Topology diagrams of KCNQ1 with KCNE1 (*upper*) and KCNE3 (*lower*) showing residues (numbered where specific residues have been identified as particularly important) and domains identified as being influential in control of KCNQ1 gating by the KCNEs. Arrows: *red*, KCNE1 or 3 control of KCNQ1 activation; *yellow*, KCNE1 control of deactivation; *orange*, KCNE1 control of inactivation; *pink*, KCNE1 control of conductance; *purple*, inter-domain interactions within KCNQ1 that are affected by KCNE1; *dashed purple*, KCNQ1 outer vestibule/selectivity filter flexibility; *dashed gray*, physical proximity and/or interaction without major functional effects. “-” = acidic residue, “+” = basic residue. Citations appear in main text.

B. Cartoon of possible orientations with respect to KCNQ1 (*blue*), based on evidence summarized in panel A, of KCNE1 (*upper*) and KCNE3 (*lower*) at resting membrane potential. S6' = the S6 of an adjoining KCNQ1  $\alpha$  subunit. KCNEs are depicted as semi-transparent to avoid concealing KCNQ1 features.

**Table 1**  
**Summary of main effects of KCNE1 and KCNE3 on Kv  $\alpha$  subunits**

See main text for expanded description of effects.

Kv $\alpha$ subunit	Effects of KCNE1	Effects of KCNE3
KCNQ1	Slows activation, strongly increases peak current in oocytes, CHO and HEK cells, and cardiac myocytes. <sup>12,13</sup>	Instantaneous activation, small increase in peak current in oocytes and CHO cells. <sup>17,33</sup>
KCNQ4	Mild upregulation in <i>Xenopus</i> oocytes. <sup>67</sup>	Inhibits in <i>Xenopus</i> oocytes. <sup>17,78</sup>
KCNQ5	Slows activation, increases peak current by decreasing inward rectification in HEK, oocytes. <sup>77</sup>	Inhibits in HEK cells and in <i>Xenopus</i> oocytes. <sup>77</sup>
hERG	Doubles current density in CHO cells. <sup>61</sup>	Strongly inhibits in <i>Xenopus</i> oocytes. <sup>8</sup>
Kv1.1	No effect in CHO cells. <sup>69,70</sup>	?
Kv1.1-Kv1.4	Increases current density 2-fold in CHO cells. <sup>69,70</sup>	?
Kv1.4	Traps in ER/Golgi in CHO cells. <sup>69,70</sup>	?
Kv2.1	Slows activation/deactivation in CHO cells. <sup>57</sup>	Slowed activation/deactivation in CHO cells. <sup>76</sup>
Kv3.1	Strongly slows activation/deactivation, accelerates inactivation in CHO cells. <sup>71</sup>	Weakly slows activation/deactivation, accelerates inactivation in CHO cells. <sup>71</sup>
Kv3.1-Kv3.2	Strongly slows activation/deactivation, accelerates inactivation in CHO cells. <sup>71</sup>	Weakly slows activation/deactivation, accelerates inactivation in CHO cells. <sup>71</sup>
Kv3.1-Kv3.4	Attenuates inactivation by "mopping" up homomeric Kv3.4 in CHO cells. <sup>69,70</sup>	?
Kv3.2	Strongly slows activation/deactivation, accelerates inactivation in CHO cells. <sup>71</sup>	Weakly slows activation/deactivation, accelerates inactivation in CHO cells. <sup>71</sup>
Kv3.3	Inhibits, probably by trapping in ER/Golgi in CHO cells. <sup>69,70</sup>	?
Kv3.4	Traps in ER/Golgi in CHO cells. <sup>69,70</sup>	Augments activity, left-shifts voltage dependence in CHO cells. <sup>65</sup>
Kv4.2	No effect (with $\alpha, \beta$ staggered injection) in <i>Xenopus</i> oocytes. <sup>73</sup>	Inhibits in CHO cells and In SGNs. <sup>72</sup>
Kv4.3	Slows gating, increases current in HEK cells. <sup>75</sup>	Inhibits in CHO cells. <sup>74</sup>
Kv4.3-KChIP2	Accelerates activation. Mildly speeds, slows recovery of, and left-shifts steady state inactivation; all in CHO cells. <sup>76</sup>	Accelerates activation. Strongly speeds, slows recovery of, and left-shifts steady state inactivation; all in CHO cells. <sup>76</sup>
Kv12.2	Inhibits in <i>Xenopus</i> oocytes. <sup>67</sup>	Inhibits <i>Xenopus</i> oocytes. <sup>67</sup>

**Table 2**  
**KCNE1 gene variants associated or putatively associated with human disease**

AF, Atrial Fibrillation; AV block, atrioventricular block; BrS, Brugada Syndrome; diLQTS, drug induced Long QT Syndrome; diTdP, drug induced torsade de pointes; fs, frame shift; JLNS, Jervell and Lange-Nielsen Syndrome; n.r., not reported; RWS, Romano-Ward Syndrome; Sources include cited papers and <sup>162</sup>. KCNE1 gene accession number: P15382.

Mutation	Disease	<i>In vitro</i> cellular effects
T7I	JLNS <sup>85</sup>	n.r.
A8V	LQT5, AF	I <sub>Ks</sub> +9 mV positive shift in V <sub>1/2</sub> activation. No change in deactivation or activation time constants. I <sub>Kr</sub> loss of function. <sup>134,135</sup>
T10M	LQT5 <sup>135</sup>	n.r.
W17X	LQT5 <sup>135</sup>	n.r.
G25V	Lone AF	I <sub>Ks</sub> gain of function <sup>95</sup>
S28L	LQT5, AV block (neonatal)	n.r. <sup>135,136</sup>
R32H	LQT5	Gating not altered <sup>135,137,138</sup>
38G versus 38S	AF, AF in elderly patients, postoperative AF, LQT5	I <sub>Ks</sub> loss of function, reduced membrane K <sub>v</sub> 7.1 (KvLQT1) channel <sup>93,97,139-144</sup>
38G versus 38S	Ménière's disease (Japanese cohort; not recapitulated in study of Caucasian population) <sup>122,123</sup>	n.r.
V47F	LQT5	hERG Gain of Function <sup>145</sup>
L51H	LQT5	Does not process properly, not found in membrane <sup>145</sup>
G52R	LQT5	I <sub>Ks</sub> reduced 50% <sup>146</sup>
G55S	LQT5 <sup>135</sup>	n.r.
T58P	LQT5 <sup>135</sup>	n.r.
L59P	LQT5 <sup>135</sup>	n.r.
G60D	Lone AF	I <sub>Ks</sub> gain of function; faster deactivation <sup>95</sup>
R67C	LQT5 <sup>135</sup>	n.r.
R67H	LQT5 <sup>135</sup>	n.r.
K70M	LQT5 <sup>135</sup>	n.r.
K70N	LQT5 <sup>147</sup>	n.r.
S74L D76N	LQT5 (JLNS+RW) <sup>24</sup> diLQTS <sup>148</sup>	D76N: I <sub>Ks</sub> - smaller unitary currents and open probabilities; dominant negative <sup>26</sup> I <sub>Kr</sub> - loss of function <sup>145</sup> S74L: I <sub>Ks</sub> - loss of function <sup>149</sup>
N75-fs+34X	LQT5 <sup>135</sup>	n.r.
Y81C	LQT5?	I <sub>Ks</sub> loss of function, Positive shift for voltage of activation <sup>150</sup>
E83K	LQT5 <sup>135</sup>	n.r.
D85N	LQT5? DiLQTS DiTdP	No effect on I <sub>Ks</sub> V <sub>1/2</sub> of activation, or deactivation properties <sup>148,151-159</sup>
W87R	LQT5	I <sub>Ks</sub> loss of function, altered gating <sup>145</sup>

<b>Mutation</b>	<b>Disease</b>	<b><i>In vitro</i> cellular effects</b>
R98W	LQT5?	Disrupts I <sub>Ks</sub> trafficking, right-shifts voltage dependence of activation <sup>160</sup>
V109I	LQT5	I <sub>Ks</sub> loss of function (36%) <sup>161</sup>
Q117X	LQT5 <sup>135</sup>	n.r.
T125M	LQT5 <sup>135</sup>	n.r.
P127T	LQT5, RWS <sup>137</sup>	n.r.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 3**  
**KCNE3 gene variants associated or putatively associated with human disease**

AF, Atrial Fibrillation; BrS, Brugada Syndrome; fs, frame shift; LQTS, Long QT syndrome; n.r., not reported; Sources include cited papers and <sup>162</sup>. *KCNE3* Gene accession number: Q9Y6H6.

Mutation	Disease	<i>In vitro</i> cellular effects
T4A	LQTS? BrS	No effect on I <sub>Q1-E3</sub> <sup>163</sup> I <sub>to</sub> gain of function <sup>126</sup>
V17M	AF	K <sub>V</sub> 4.3 and K <sub>V</sub> 11.1 (hERG) gain of function <sup>127</sup>
R53H	AF	I <sub>Q1-E3</sub> gain of function <sup>164</sup>
F66F (198T/C synonymous switch)	Ménière's disease (Japanese cohort; not recapitulated in study of Caucasian population) <sup>122,123</sup>	n.r.
R99H	BrS LQTS?	K <sub>V</sub> 4.3, I <sub>to</sub> gain of function <sup>74</sup> I <sub>Q1-E3</sub> Loss of function <sup>163</sup>
R83H	Periodic paralysis (but also detected in asymptomatic individuals in a later study) <sup>65,120,121</sup>	K <sub>V</sub> 3.4 loss of function and increased sensitivity to proton block <sup>65</sup>